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Ischaemia is often a medical emergency, clinical signs and symptoms vary dependant on 
organ or organ system affected. Timely restoration of oxygen delivery to affected tissues is 
paramount to preventing morbidity and mortality. Current diagnostic aids are non-specific 
and often late markers of ischaemia where there has been irreversible tissue damage. 
 
Metabolism of adenosine triphosphate (ATP) is altered during periods of ischaemia and 
intermediate nucleosides such as adenosine, inosine and hypoxanthine are released into the 
systemic circulation in demonstrable quantities. Development of an amperometric biosensor 
sensitive to these purine nucleosides, produced early in ischaemia prior to cell death, gives 
potential for purine nucleosides to be a clinically relevant biomarker. 
 
Methods 
A series of prospective observational cohort studies have been designed to provide pilot data 
on purine nucleoside changes, measured in real-time in vivo in populations of both surgical 
and non-surgical patients where a simple test for early identification of ischaemia would be 
clinically useful expedite diagnosis and prevent patient harm. 
 
Results 
There was no significant variation from baseline readings in purine nucleosides in 
systemically obtained samples intra-operatively in patients who are anaesthetised with 
general anaesthetic. There were significant increases in nucleosides in blood samples 
obtained locally within acutely ischaemic tissue. Elevated purine nucleosides were also 
identified in patients with critical limb ischaemia and following some types of brain injury. 
 
Conclusions 
Reliable determination of purine nucleosides in vivo remains challenging; multiple factors 
may interfere with quantification in vivo. Results here have identified purine nucleosides may 
have a role in acute and chronic limb ischaemia as well as traumatic brain injury. This 
requires further validation in populations of patients in clinical practice. Expansion to further 






Ischaemia is defined as a restriction in blood flow (and therefore oxygen delivery) to tissues. 
The effect of prolonged ischaemia is ultimately cellular death, the effect of which will vary 
dependant on the anatomical location and metabolic requirement of tissue in relation to the 
extent of ischaemic insult. In general, the mainstay of treating ischaemic events is the 
restoration of blood flow. To offer patients the best prognosis this should be achieved as 
quickly as possible. Reliable biomarkers of ischaemia are of clinical importance to aid 
diagnosis and guide management in a timely manner. Currently there are very few 
biomarkers of ischaemia that are widely used in clinical medical practice.  
 
The purinergic role in vivo is multifaceted and varies significantly throughout the human 
body. Their role includes regulatory, retaliatory and anti-inflammatory functions as well as 
neurotransmission and regulation of blood flow (1-4). There is also evidence of an acute rise 
in purine nucleoside concentrations in response to hypoxia and ischaemia in an experimental 
setting (5, 6).  
 
This body of work sets out proof-of-concept data on the evaluation of adenosine triphosphate 
(ATP) metabolism in the form of the purine nucleosides adenosine inosine and hypoxanthine 
as biomarkers of ischaemia across a range of ischaemic conditions in clinical medical 







1. Review of ATP metabolism in ischaemia and its potential use as a 
biomarker in vivo 
 
1.1 Mechanisms of ATP metabolism in ischaemia 
Adenosine triphosphate (ATP) is the essential currency in mammalian cellular metabolism 
(7). In resting conditions a continuous supply of ATP is generated within mitochondria via 
oxidative phosphorylation in the electron transport chain (8). During periods of hypoxia 
and/or ischaemia ATP can be generated by both glycolysis or production of lactate but this is 
inefficient and short lived, therefore ATP generation ceases within minutes (9). To continue 
energy production intracellularly, ATP is metabolised along enzymatically regulated 
cascades ending with the formation of uric acid (10). The mechanism and pattern of purine 
production and release varies between cell types within the same tissue or organ and between 
different tissue types throughout the body (11). In general, after the onset of ischaemia 
oxidative phosphorylation to produce ATP ceases. Existing ATP and adenosine diphosphate 
(ADP) are cleaved of their remaining phosphate(s) by hydrolysis to form adenosine 
monophosphate (AMP). Activation of 5’nucleosidase and AMP-deaminase in the cytosol 
leads to metabolism of adenosine monophosphate into adenosine and inosine.  
 
Both adenosine and inosine can be transported across cell membranes by equilibrative 
nucleoside transporters (ENTs) (12) into the interstitial space where further metabolism, 
catalysed by purine nucleoside phosphorylase, to hypoxanthine can occur. These purines 
have low molecular weight and therefore are free to pass into the systemic blood circulation 
relatively unimpeded allowing their detection at sites distant to the area of ischaemia (13). 
Further metabolism to xanthine and uric acid are both oxygen dependant (via xanthine 
oxidase) and therefore inhibited whilst hypoxia and/or ischaemia are ongoing and as such not 
produced during ischaemia (14).  
 
In addition to this intracellular metabolism cascade there is also an extracellular pathway for 
adenosine production known as the cyclic-AMP (c-AMP) – adenosine pathway (15). There is 
active transport of c-AMP into the extracellular space as well as transport of ATP across cell 
membranes, this can occur directly via exocytosis or gap junction hemi channels within the 
central nervous system (CNS) (16). c-AMP and adenosine can then be metabolised to liberate 
adenosine via membrane bound ecto-phosphodiesterase and ecto-nucleosidases (CD39 and 
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CD73) (17-19). A diagrammatic representation of the purine metabolism pathways is shown 

































1.2 Evolution of techniques for assessment of purine concentrations  
1.2.1 Frozen tissue 
Historically, the short half-life and multiple sites of re-utilisation of purines (20-22) lead 
assessment techniques to revolve around rapidly freezing tissue samples with liquid nitrogen 
prior to analysis. This technique instantly stops ongoing purine metabolism therefore accurate 
determination of nucleoside concentrations can be achieved. The need for excision of tissue 
and rapid freezing is destructive and has restricted its use to animal models as well as limiting 
its potential application in human research settings and clinical medical practice (23, 24). 
 
1.2.2 Interstitial fluid (via microdialysis) 
Tissue interstitial purine concentrations became of interest with the advent of microdialysis 
(25). Fine bore cannulae can be inserted into tissues between cells and flushed with a 
perfusate. Over time purine concentrations equilibrate between perfusate and interstitial fluid 
that then can then be collected and analysed. Microdialysis allows direct assessment of 
extracellular purine nucleosides and when compared to rapid freezing, cannula insertion is 
significantly less traumatic. Transient rises in purine concentrations attributed to local release 
following insertion have been identified though these are minor and short lived (26). It also 
requires the site of ischaemia to be readily accessible for cannula insertion and is therefore 
limited to peripheral sites of ischaemia. Sample collection can be time consuming as a period 
must be allowed for equilibration between interstitial fluid and dialysate. Though periods of 
less than one minute have been reported, typical collection periods used can be around ten 
minutes (27). Recovery percentage of the nucleosides is inversely proportional to dialysate 
flow rate. Percentages can be increased by slowing flow rate but collection time periods may 
then become further extended (28, 29).  
 
1.2.3 Cerebrospinal fluid 
Analysis of purine nucleosides is possible from cerebrospinal fluid (CSF) samples (30-32) in 
humans via lumbar puncture. Though this mechanism of sampling is limited by its invasive 
nature, risk of significant complications (such as paraplegia) and requires skilled clinicians to 
perform it in a controlled setting. This again limits its widespread use, especially in the 






Arterial, venous and capillary blood sampling is part of routine clinical practice and therefore 
obtaining samples is minimally invasive and easily achievable. Analysis of blood samples 
was initially confounded by ongoing enzymatically mediated metabolism as well as purine 
release from, and uptake into, platelets and erythrocytes after sampling but before sample 
analysis. This necessitated development of blocker solutions to preserve samples prior to 
analysis. A blocker solution should contain an adenosine deaminase inhibitor, an adenosine 
reuptake inhibitor and a 5’ecto-nucleosidase inhibitor. Erythro-9-(2-hydroxy-3-nonyl)adenine 
(EHNA), dipyridamole and alpha-beta-methylene-ADP (AOPCP) or 
ethylenediaminetetraacetic acid (EDTA) have been used respectively, in various 
combinations, to achieve this (33-36). In order for the blocker solution to achieve maximum 
efficacy it has to be introduced to blood at the earliest possible opportunity after sampling. 
Dedicated cannulae have been designed for mixing of the blocker and sample to occur 
immediately after sampling (4, 37). This mixing can then be followed by deep freezing until 
analysis.  
 
1.3 Analysis of biological samples 
1.3.1 High performance liquid chromatography 
The first widely used analysis technique for samples was high performance liquid 
chromatography (HPLC). HPLC is both sensitive and specific for determination of 
concentrations of constituents of complex biological samples, such as blood, interstitial fluid 
or CSF. In addition it requires small volumes to analyse and is faster than traditional 
chromatography (38). There are also multiple drawbacks to the use of HPLC in clinical 
medicine samples require preparation prior to analysis (deproteinisation) and analysis 
requires specialist equipment and operator skills to ensure reliable results (39). This means it 
is not scalable into hospital laboratories and remains a method of analysis in a research 
setting only.  
 
1.3.2 Optical detection 
Optical detection methods such as fluorescent and chemiluminescent analysis techniques 
have been widely used (40, 41). These both rely on enzymatic metabolism of purines by 
adding adenosine deaminase and/or xanthine oxidase to the sample to produce hydrogen 
peroxide (H2O2). This H2O2 can then react with reagents that will fluoresce when light is 
applied (e.g. difluorescin) or luminesce without an external light source (e.g. luminol). The 
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strength of the light emitted can then be measured and converted to an integer by comparison 
with a calibration measurement from a signal given by known concentration of purine 
nucleosides. Both of these techniques have been validated as highly sensitive and specific. 
Analysis time is significantly shorter than HPLC and detection equipment is cheaper (5, 42). 
Results can be affected by background interference and signals emitted from other biological 
compounds. Results can also be disturbed by alterations in reaction conditions such as 
temperature and pH (43-45). As with HPLC, samples often require deproteinisation prior to 
analysis. A chemiluminescent sensor has been validated in vivo in patients presenting to the 
emergency department with chest pain (5). 
 
1.3.3 Electrochemical detection 
Enzyme based electrochemical (amperometric) biosensors (6, 46) function in a similar way to 
their optical counterparts. Enzymatic formation of H2O2 induces a change in current around 
an electrode which can then be interpreted as an integer. The advantages of electrochemical 
sensors are short analysis duration (in the order of seconds) and allowing analysis of 
unprepared samples (47, 48). They remain susceptible disturbance in sensing due to 
interference from other biological compounds within the sample, electrode fouling and 
variations in temperature or pH (46, 49).  Amperometric biosensors have been utilised to 
observe changes in purine concentration in patients undergoing carotid endarterectomy (6). 
 
Other techniques such as radioimmunoassay, nuclear magnetic resonance spectroscopy and 
mass spectroscopy have been described for the quantification if purine nucleosides in vitro 
with reliable results (50-52). However, their use has limitations context of time-critical 
assessment of ischaemia. These include use of radioactive isotopes, expensive specialist 
equipment, the need for sample preparation and prolonged analysis duration.  
 
1.4 Purines as biomarkers 
There has been interest in purines as an early clinical biomarker in ischaemia and hypoxia as 
traditional biomarkers of tissue ischaemia (e.g. lactate and acid-base disturbance) are late and 
non-specific (53). Studies have focused on a wide range of ischaemic and hypoxic scenarios 





Early animal models 
1.4.1 Cerebral Ischaemia  
The brains’ unique role, relative physiological isolation by means of the blood brain barrier 
(BBB) and requirement for high energy substrate to function leaves it particularly vulnerable 
to injury caused by periods of hypoxia or ischaemia (54). Purine release in response to 
cerebral metabolic stress has been investigated since the 1960s (55, 56).  
 
Rapid, significant rises in adenosine concentrations were recorded in brain tissue and 
interstitial fluid in rats, measured by cortical freeze blowing, up to 60 seconds after inducing 
hypotension and subsequent brain ischemia by aortic transection (mean peak adenosine 1.28 
nmol/g control vs 5.50nmol/g at 60 seconds, p<0.001) (23). No significant changes in 
hypoxanthine were noted. The same group measured a ten-fold increase in cerebral interstitial 
concentrations of adenosine during ten minute periods of hypoxia and a four-fold increase ten 
minutes after ceasing respiration in anaesthetised rats (56).  
 
In order to measure extracellular changes Laudignon et al and Park et al (32, 57) identified 
increases in adenosine in CSF samples obtained from direct puncture of the cisterna magna in 
piglets. These results were supported by Phillis et al (31) who found adenosine increased in 
the CSF of rats during hypoxia and that this increase was dependant on increasing hypoxia 
(Adenosine peak at 14% inspired oxygen concentration (FiO2) 261±130nmol/L vs FiO2 5% 
peak 331.9±133.65nmol/L). Progressive asphyxia of foetal lambs (58) resulted in a four- to 
six-fold increase in hypoxanthine from central venous samples. Results from this study 
showed no difference in peripheral arterial or venous concentrations. Plaschke et al (59) 
showed that in rats having undergone staged (over the course of five days) bilateral carotid 
and vertebral artery ligation exhibited sustained two-fold increase above control values in 
adenosine within cerebral tissue at two weeks post completion of four vessel occlusion.  
 
1.4.2 Cardiac Ischaemia  
Adenosine was first proposed separately in the early 1960s by Berne (60) and Gerlach and 
Deuticke (61) to play a role in regulating blood flow in cardiac tissue in order to balance 
supply and demand of oxygen (O2) via its action as a potent vasodilator (62, 63). This theory 
became known as the adenosine hypothesis was generally accepted for a significant period of 
time. It has since been observed that administration of adenosine deaminase fails to reduce 
reactive hyperaemia to decreased O2 saturations in myocardial tissue (64) leading to the 
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theory that although adenosine and other nucleosides increase during ischaemia they cannot 
not be the sole regulator to changes in myocardial blood flow. It is now accepted that 
endothelial release of nitric oxide is responsible for initial changes in coronary blood flow in 
response to hypoxia (65).  
 
There has been extensive investigation into changes in cardiac purines. It was theorised that 
rises in purines would be pronounced in cardiac ischaemia as mitochondria account for up to 
50% of myocyte cellular mass (13) in order to meet energy demand. Current gold standard 
cardiac enzyme tests (Troponin I and troponin T) used for diagnosis of myocardial ischaemia 
are indicative of irreversible cellular damage and tissue necrosis (38). As purine release 
occurs from viable cells under ischaemic stress it was considered purines may be useful as an 
earlier indicator of cellular ischaemic stress that the current tests. 
 
Canine studies (66, 67) measured changes in adenosine, hypoxanthine and inosine in cardiac 
interstitial fluid via microdialysis catheters implanted into left ventricle myocardium. In the 
first study regional myocardial hypoxia was induced by perfusing the left anterior descending 
artery with deoxygenated venous blood. This allowed systemic SaO2 to remain normal so 
changes in purine concentrations were solely in response to reduced myocardial oxygen 
supply. A significant rise in adenosine was only identified in dialysis catheters primed with 
an EHNA containing stopping solution. Dialysate hypoxanthine and inosine increased in a 
similar fashion to adenosine. In a second study, reactive hyperaemia was prevented with 
blood flow being restricted to normoxic levels in periods of hypoxia, preventing extra O2 
delivery with extra blood flow. This induced a rise in adenosine greater than that when a 
normal physiological response to hypoxia in coronary blood flow was permitted (14% vs 
53% increase p<0.05). In this study levels of hypoxanthine and inosine were elevated on 
administration of exogenous adenosine deaminase that also caused a fall in adenosine. These 
findings were replicated in HPLC measurements of canine pericardial fluid by Kekesi et al 
(68) during periods of coronary artery spasm induced by intracoronary administration of 
endothelin-1 (ET-1).  
 
Porcine experimental models have been used widely as their coronary circulation closely 
mimics humans. Unlike in canine hearts, occlusion of a single vessel induces ischaemia due 
to a lack of adequate collateral circulation. Studies of coronary venous and arterial purines 
after ischaemia induced by a snare or clamp around the left anterior descending artery all 
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produced similar results. De Jong (69) recorded significant increases in inosine and 
hypoxanthine in venous samples during ischaemia but arterial samples obtained at the same 
time points remained at base values. Backstrom et al. (70) divided pigs into cohorts 
undergoing varying lengths of cardiac ischaemia and analysed samples obtained from the 
great cardiac vein, external jugular vein and pulmonary artery. Results indicated the only 
significant rise occurred in samples from the great cardiac vein. Rises in hypoxanthine were 
related to duration of ischaemia, +150% at 15 minutes (p<0.01 vs baseline) and +415% at 45 
minutes of ischaemia (p<0.001 vs baseline). A plateau was demonstrated after 45 minutes of 
ischaemia followed by a further rise within the first 15 minutes of reperfusion peaking at 
+590% against baseline (p<0.001). This plateau phase may indicate complete depletion of 
mitochondrial ATP stores followed by a degree of reperfusion injury on restoration of flow. 
This late rise has been demonstrated in other experimental settings (see later). Wikstrom (71) 
identified an initial rise in adenosine after 15 minutes of ischaemia in interstitial myocardial 
dialysate this rise was not sustained and declined to pre-ischaemic levels after 50 minutes of 
ischaemia. Hypoxanthine and inosine were elevated during the whole of the ischaemic 
period. Ramani et al. (72) set out to identify differences in purine metabolism with increasing 
age in rats. They found older rats showed significantly faster ATP depletion and a 
significantly lower adenosine rise than in younger rats. A changing profile of nucleoside 
release with increasing age would be an important factor when considering interpretation of 
purine concentrations as an investigation in a clinical setting.  
 
1.4.3 Global hypoxia  
There has been significant interest in purines as a biomarker against a background of global 
hypoxia alongside conventional markers. It was hypothesised that purines may be a more 
specific biomarker as both lactate and base deficit may be elevated in pathological conditions 
other than hypoxia (53). 
 
Initial canine studies into the relationship between purine changes and hypoxia revealed very 
little change in arterial concentrations but did show significant central venous increases, 
subsequently high xanthine oxidase activity was found in canine lungs promoting degradation 
of hypoxanthine to uric acid (73) thus accounting for low arterial concentrations. Unlike 
canines rats, pigs and humans lack lung xanthine oxidase (74). Rodent studies have shown a 
mean arterial adenosine increase from 79.2±12.7µmol/l to 190.2±32.2µmol/l on induction of 
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hypoxia (FiO2 8%)(75). Saugstad and Assen (74) also  recorded significant rises in arterial 
hypoxanthine in pigs with severe hypoxia (FiO2 7%). Conde (20) investigated adenosine 
release from rat carotid bodies, the primary mammalian chemoceptor involved in response to 
hypoxia, during progressively decreasing oxygen partial pressures (10%, 5% and 2% FiO2). 
Adenosine release was positively associated with increasing duration of hypoxia, a 31% 
increase at ten minutes’ vs 44% increase at 30 minutes (P<0.0001) In addition, it was also 
demonstrated that increasing severity of hypoxia induced greater adenosine release from the 
Carotid artery endothelium.  
 
1.4.4 Skeletal Muscle and Peripheral Tissues 
Skeletal muscle and other peripheral tissues are relatively more resistant to ischaemic injury 
when compared to myocardium or cerebral tissue (62, 76). It has also been hypothesized that 
tissue injury occurs both during ischaemia and on reperfusion by oxygen free radical 
production in energy depleted cells (77, 78). Much research has been performed into 
adenosine and the purine nucleosides as regulatory and retaliatory substances in peripheral 
ischaemia, comparatively less work has been undertaken as purines as marker of ischaemia 
and/or tissue damage. Ihnken et al (77) induced  acute hind limb ischaemia in pigs followed 
by restoration of flow to simulate femoral artery embolectomy and found uncontrolled 
reperfusion lead to a greater drop in ATP with subsequent increased purine nucleosides when 
compared to graded reperfusion over a number of minutes. Mo and Ballard (79) measured 
arterial, venous and interstitial adenosine changes in the gracilis muscle of anaesthetised dogs 
in hypoxia and during exercise (by direct electrical muscle stimulation) and found venous 
concentration of adenosine significantly increased 350±52hmol/l to 518±107hmol/L during 
hypoxia whereas interstitial adenosine significantly increased during exercise. There was no 
change in arterial purines during hypoxia or exercise.  
 
Progression to Purinergic role in human ischaemia  
1.4.5 Cerebral Ischaemia 
There have been several studies into ischaemic production of purine nucleosides in vivo in 
humans. Initially these used carotid endarterectomy (CEA) as a model of controlled 
reversible, reproducible cerebral ischaemia. Weigand et al (80) measured changes in 
ipsilateral jugular venous adenosine and hypoxanthine in patients undergoing CEA with a 
general anaesthetic (GA). They demonstrated significant rises in adenosine and hypoxanthine 
 33 
when compared to time-matched peripheral arterial samples in patients exhibiting loss of 
somatosensory evoked potentials (SSEP) during interruption of carotid blood flow (229-
338nM). Loss of SSEPs suggests inadequate collateral blood supply, rendering the cerebral 
hemisphere ipsilateral to the CEA ischaemic. No significant changes were noted in patients 
where SSEPs were maintained. Tian et al (6) found a 2.8-fold increase from baseline in 
median peripheral arterial purine concentrations in patients undergoing CEA with loco-
regional anaesthesia (LA) regardless of shunt use (2.4µM-6.7µM). A subgroup of patients 
within this study lost consciousness soon after carotid clamping and required shunt insertion. 
In this group baseline purines were significantly higher than those not requiring shunt 
insertion and shunt use was associated with a fall to below baseline levels of purines.   
 
Elevation in purine nucleosides in patients presenting to secondary care with radiologically 
confirmed stroke, when compared with healthy controls, has been demonstrated using the 
same biosensor as used in the Tian et. al. study. Mean baseline purines were 7.1±4.2µM in 
controls and 11.6±8.9µM in stroke patients (81). This elevation was universal to mild 
moderate or severe stroke, graded by the national institute of health stroke scale. The same 
group also noted a correlation between baseline purines and early neurological deterioration 
in stroke patients (82). Prior to this, Laghi-Pasini et al (83) conducted a study measuring 
peripheral venous adenosine daily in patients presenting with clinically confirmed transient 
ischaemic attack (TIA) or stroke. They found adenosine was significantly raised on 
presentation to hospital and continued to rise, peaking on day two and day three of admission 
before declining to a stable level by days five and 15 post event respectively. 
 
Purine release from the brain during ischaemia is not in doubt. Whilst ischaemia induced 
during CEA is reversible and milder than in stroke, peak adenosine was higher in the CEA 
study of Tian than that of stroke patients in the Pasini study (6.7µM vs 290nM). The 
discrepancy in results between these studies is likely to be related to advancement in 
detection methods i.e. increasing sensitivity in the detection of adenosine by electrochemical 
enzyme assay compared to HPLC. Peak adenosine in the Pasini and Weigand studies are 
comparable (290nM vs 229nM) and used similar analysis techniques. The CEA studies 
identify purine release is rapid following onset of ischaemia with rapid return towards 
baseline values with restoration of flow. Prolonged elevation identified in stroke patients may 
ether be representative of greater degree of injury or ongoing ischaemia as there was no 
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intervention to restore cerebral perfusion in any of the patients studied. The pattern of purine 
release in the patients requiring shunt insertion in the study of Tian et al lends support to 
other work in rodents (59) that identified raised baseline purine concentrations in subjects 
with chronically ischaemic tissues compared to those with normal tissue perfusion. 
 
Carotid endarterectomy carries a 2% procedural risk of stroke (84). Large scale meta analyses 
have been unable to demonstrate superiority of routine vs selective shunting to protect against 
hypoperfusion injury of the brain during CEA (85) and current methods of intraoperative 
cerebral monitoring have not been proven effective (86).  Stroke remains a clinical diagnosis 
via the face, arm speech test. Larger scale studies in stroke patients are needed as a rapid 
reliable peripheral blood marker may serve to expedite diagnosis and therefore treatment in 
stroke patients where early intervention can be critical to limiting ischaemic injury and 
improving neurological outcomes (87). The amperometric biosensor used by Tian et. al. and 
Dale et. al. study allows analysis in real time from whole unprocessed blood. Results above 
would suggest that purines are a sensitive marker of ischaemia that can be detected by 
peripheral sampling of whole blood and, with further investigation, may be able to offer a 
simple clinical test to assess cerebral perfusion in a range of settings. 
 
1.4.6 Cardiac ischaemia 
Current gold standard cardiac enzyme tests (Troponin I and troponin T) are indicative of 
irreversible cellular damage and tissue necrosis (38). As purine release occurs from viable 
cells under ischaemic stress it was considered purines may be useful as an earlier indicator 
that the current tests. Early human studies identified significant elevation in coronary venous 
inosine and hypoxanthine during rapid atrial pacing and exercise in patients with coronary 
artery disease after the onset of anginal chest pain. These purine changes were not replicated 
in patients without angina symptoms or in those with cardiac failure (88-90). These findings 
suggested purine release is specific to ischaemic myocardium rather than a general response 
to increased metabolic demand. Bardenheuer et al. (91) went on to identify purine rise is 
proportional to duration of coronary artery occlusion (30, 60 or 90 seconds) in patients with 
coronary artery disease undergoing percutaneous transluminal angioplasty. Farthing et al. 
(13) recently developed a chemilluminescence method of testing to identify rapid purine 
changes in venous plasma in patients presenting to the emergency department with non-
traumatic chest pain. They found significantly elevated inosine and hypoxanthine in 
peripheral venous sampling in patients with confirmed myocardial infarction (MI).  
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This study is unique in validating the findings of the previous experimental models in a 
clinical setting with direct application to myocardial infarction. Furthermore, their novel 
method of testing for purines was able to appreciate significant increases via peripheral 
venous sampling with a short analysis time. Combined, these two factors offer promise for 
testing of purines as a useful biomarker.  A summary of the findings of the discussed studies 












Table A: Summary of studies reporting purine release during cardiac ischaemia. For ease 




Study Year Sampling  Patient group(s) Mean baseline 
purine  
Mean peak purine  
Fox et al. 1974 Coronary 
venous 
effluent 
Patients under investigation 
of coronary artery disease. 
Rapid pacing 
Unable to detect 400nmol/l 
 
Unable to detect in non-
angina sufferers 
Remme et al. 1976 Coronary 
venous 
effluent 
Patients under investigation 








No change in non-angina 
sufferers 
Kugler et al. 1979 Coronary 
venous 
effluent 
Angina sufferers only:  





 Inosine: 1510nmol/l* 
 Hypoxanthine: 1640 
nmol/l 
Exercise  








Patients with known 
coronary artery disease. 










Farthing et al. 2011 Peripheral 
venous 
blood 
Patients presenting to 
emergency department 
with chest pain. 
Not given Not given 
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1.4.7 Systemic hypoxia 
Following studies identifying large rises in arterial adenosine during induced systemic 
hypoxia in rodent and porcine studies (20, 74, 75) human studies have been less conclusive. 
Tuchschmid et al. (92) failed to demonstrate any significant increase in venous hypoxanthine 
during hypoxia of simulated 6000m altitude (FiO2 10%) or during hypoxia combined with 
exercise. Saito et al. (34) measured peripheral adenosine concentration changes during 
normoxia and moderate hypoxia (SaO2 80%). Significant rises in adenosine were observed at 
20 minutes of hypoxia although this was only noted in participants commenced on an 
intravenous dipyridamole infusion, acting as an adenosine reuptake inhibitor, prior to 
induction of hypoxia. Maclean et al. (26) measured interstitial hypoxanthine from catheters 
inserted between fibres of the vastus lateralis muscle in healthy males at normoxia and 
periods of hypoxia (FiO2 10.5%). Adenosine levels doubled from baseline within 15 minutes 
and remained elevated as hypoxia continued.  
 
There are methodological differences to account for the discrepancy between the human and 
animal studies. The degree of hypoxia induced in the animal studies was more severe and 
resulted on the death of the study subjects (FiO2 below 10% compared to SaO2 maintained at 
80% by Saito et al). Increases following pre-treatment with dipyridamole indicates purine 
release does occur in humans but there may be systemic reuptake of nucleosides confounding 
analysis of study samples. From this it could be concluded that demonstrable purine release 
may only be achieved at a level of systemic hypoxia that it is not possible to replicate safely 
in humans under experimental conditions. If this is the case in clinical practice, pre-existing 
clinical measures, such as peripheral saturation probes or arterial blood gas analysis, are 
currently available to quickly and safely identify patients who are hypoxic. 
 
1.4.8 Exercise 
Patterson et. al. (93) identified significant increases in venous hypoxanthine during exercise 
from peripheral venous samples in healthy adults undergoing forearm exercise testing with a 
grip dynamometer. Two further studies reported similar results in “semi ischaemic” forearm 
testing whereby a tourniquet on the upper arm was inflated to mean arterial pressure (MAP) 
before exercise was started (29, 94). Hellsten et al. (95) demonstrated increases in interstitial 




1.4.9 Peripheral arterial disease 
Sørlie et al. (96) demonstrated a rise in popliteal venous hypoxanthine on exercise in both 
patients with peripheral arterial disease (PAD) and healthy controls. However, the PAD 
patients had significantly higher basal hypoxanthine than the controls and exhibited a similar 
rise as the controls with less strenuous exercise. Similarly, Rexroth et al. (97, 98) studied 
changes in arterial and venous hypoxanthine in patients with peripheral arterial disease 
(PAD) compared to healthy subjects during exercise. Venous hypoxanthine levels increased 
significantly during the recovery period post exercise in the PAD group compared to no 
change in the control group, again after undertaking less strenuous exercise.  
 
1.4.10 Surgery 
Karg et al. (99) investigated purine metabolism in ischaemic tissue in patients undergoing 
total knee arthroplasty (TKA) with the use of a lower limb tourniquet inflated to twice 
systolic blood pressure, which serves to make the limb ischaemic. They sampled both venous 
effluents from the operated leg and from an antecubital upper limb vein. Results 
demonstrated a peak hypoxanthine in the femoral vein samples 5 minutes’ post release of the 
tourniquet. Elander et al (76) analysed biopsies of microvascular free transfer flaps prior to 
dissection, during ischaemia and after flap reperfusion. Mean hypoxanthine concentration 
increased seven-fold from baseline at 1 hour of ischaemia.  
 
The multitude of studies clearly identify purine release from peripheral tissues under 
physiological stress from hypoxia, exercise, ischaemia or surgery. Purine release has been 
demonstrated to be sustained during ischaemia and proportional to degree of cellular 
metabolic stress. The study of Karg et al is of interest as it demonstrated a peak purine 
concentration after tourniquet release representing restoration of outflow from the limb on 
reperfusion. Peak nucleoside concentrations were also significantly higher compared to the 
other studies discussed. The mean ischaemic time was 85 minutes; this was a significantly 
longer period of ischaemia than the studies using an upper arm tourniquet. Purine release 
from surgically “damaged” tissue may also be a confounding factor in these results, though 
no samples were obtained from tissue distal to the tourniquet whist it was inflated to assess 
evolution of purine release in relation to stage of procedure. In the Rexroth study there was 
no intervention to induce ischaemia therefore the delay in purine nucleoside peak may be 
representative of reduced inflow to the limb and therefore delayed efflux. As in the CEA 
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studies, there was again the finding of increased resting purine nucleosides in those with 








































Table B: Summary of results of studies reporting purine nucleoside changes during 
peripheral ischaemia or hypoxia. For ease of interpretation all results have been 
standardised to µmol/l. *=statistical significance.  
 
  





1982 Peripheral venous sample 
during forearm exercise 





1982 Lower limb venous 
hypoxanthine in PAD and 
healthy controls  
Exercise only Not given Higher resting hypoxanthine 
in PAD* 




1988 Peripheral venous sample 
during forearm exercise 
(with tourniquet) 





1989 Lower limb venous 
hypoxanthine in patients 
with PAD 





1992 Interstitial fluid from 
vastus lateralis  
Hypoxia: 30 minutes at 
FiO2 10.5% 
0.44 µmol/l 1.03µmol/l* 
Elander et 
al. 
1994 Tissue biopsy of free 
transfer flaps  
pre, intra and post flap 
transfer 
Not given 100% increase in inosine 
after 1hr of ischaemia*, 




1997 Lower limb and upper 
limb venous hypoxanthine 
in surgery with a 
tourniquet) 
Lower limb surgery with 
tourniquet at 2x MAP 
Not given 100-fold rise at 5 minutes 
post tourniquet release* 
Helsten et 
al. 







2003 Peripheral venous sample 
during forearm exercise 
(with tourniquet) 






1.4.11 Other tissues and clinical applications  
There has been work carried out into purine release in other tissues, though comparatively 
less than the work described above.  
 
Saugstad et al have published extensively on the clinical application of purine nucleoside 
measurements in the perinatal period (14, 73, 74, 100, 101). They identified significantly 
elevated placental and CSF hypoxanthine in perinatal hypoxia and cerebral haemorrhage 
however,  the results were confounded by significant overlap with normal infants (102). As 
maternal hypoxanthine is known to increase during labour, with potential for transfer to the 
foetus, the significance of these results has been disputed (103).  
 
It has been hypothesised that purines may be used as a marker of renal transplant graft 
function and survival (104). Studies have shown an increase in purine concentrations during 
renal transplantation, in samples obtained from the graft renal vein (105, 106).  This increase 
was linear in relation to time of ischaemia and returned to baseline on restoration of perfusion 
in the transplanted kidney. Whilst purines are sensitive for renal ischaemia in this context, 
purine rise during transplantation failed to correlate with future decline in graft function. No 
studies to date have examined purine changes in grafts known to be failing. 
 
Work was started into the potential for purines as an early biomarker of intestinal ischaemia 
as serum lactate levels may only be raised late in the disease process. Akgur (107) examined 
changes in peritoneal purine concentrations in guinea pigs with induced intestinal ischaemia. 
No significant elevation of hypoxanthine was noted despite increases in lactate. This was 
attributed to xanthine oxidase activity within the peritoneal cavity. No analysis of blood 
samples to examine serum changes in purines associated with intestinal ischaemia was 
undertaken. 
 
Purine release in response to ischaemia and hypoxia has been studied in many contexts. 
Results have demonstrated high sensitivity for ischaemia in a variety of tissues placed under 
varying degrees of ischaemic or hypoxic stress.  Early attempts at purine assessment were 
hampered by limited understanding of the complex role of purine nucleosides in vivo, 
technological limitations in obtaining samples, prolonged analysis techniques and complex 
analysis equipment. Advances such as chemiluminescent and amperometric biosensors can 
now offer relatively simplified analysis techniques and rapid ascertainment of results from 
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unprocessed biological samples. These studies indicate there is potential for assessment of 
purine nucleosides to be a clinically useful and cost-effective point-of-care biomarker of 
ischaemia with potential to improve and expedite diagnoses ultimately leading to improved 
patient outcomes following a variety of ischaemic events. Currently their use in clinical 
practice remains in its infancy. The studies described are small single centre studies that are 
heterogeneous in sampling sites and techniques with differing target tissues and experimental 
aims. In addition, these studies were mainly performed under strict experimental conditions. 
Given this, their results may not be directly transferable into clinical practice. Significant 
future work is required before purine nucleosides can be used routinely in clinical practice.  
 
1.5 Potential application of purine nucleosides within clinical practice 
Ischaemia is often a medical emergency. Adequate oxygen delivery to tissues is essential to 
maintain normal cellular activity and therefore organ function. Tissues deprived of blood 
(and therefore oxygen) have a finite period within which ischaemia can be tolerated, after 
which cells will undergo apoptosis and necrosis (108). Though this “critical” ischaemic time 
varies between tissues, prolonged ischaemia may in turn lead to a cascade of sequelae 
including temporary or permanent organ dysfunction the clinical significance of which will 
vary significantly dependant on tissue or organ involved. Restoration of blood flow to the 
affected area as quickly as is safe and practical is paramount to minimising the deleterious 
effects of ischaemia in many situations (109).  
 
Delay in intervention to re-establish tissue perfusion may be secondary to failure to recognise 
ischaemia, diagnostic uncertainty or diagnostic delay (110, 111). Many modalities of 
investigation already exist for the detection and diagnosis of ischaemia. Direct clinical 
assessment remains the cornerstone of diagnosis in any clinical scenario though the 
sensitivity of clinical signs can be variable and reliability of clinical examination may be 
variable dependant on the experience of the clinician assessing the patient (112, 113). Non-
specific indicators such as serum lactate can be used as markers of ischaemia but results can 
be confounded by sepsis, shock or lactate metabolism (114). Organ specific blood tests are 
often late markers of end organ dysfunction (troponin assays in suspected myocardial 
infarction are indicative of myocyte death (115) and thus significant myocardial damage 
occurs prior to elevations of cardiac enzymes in serum). Radiological assessment via 
computer tomography (CT) or computer tomography angiography (CTA) of a vascular 
disease or occlusion leading to ischaemia is widely and routinely  available in secondary care 
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but can result in delay and carries risk in the form of iodine-based contrast and radiation 
(116). In some situations, arterial duplex is of clinical value in ischaemia but results are 
operator dependant and specialised vascular ultrasound is not universally available.  
 
Scenarios also arise where the usual clinical signs of ischaemia are attenuated or absent 
completely, i.e. a sedated or anaesthetised patient or in patients unable to communicate due to 
illness or trauma. In addition to this, in surgical specialities, vascular control or temporary 
interruption of blood flow to tissues is necessary in order to operate safely or ischaemia is a 
recognised as a significant risk of a surgical procedure, for example spinal cord ischaemia 
following thoracic aortic aneurysm repair (117). Whilst precautions are taken to minimise 
time of interruption of flow and to ensure any collateral flow is preserved where possible, 
unrecognised or late recognition of ischaemia may result in poorer outcomes for patients.  
 
There remains a place for a simple, reliable, rapid test that could be used as either an aid in 
diagnosis of ischaemia, intra- or post-operative monitoring where there is potential for 
ischaemic complications. In conjunction with the University of Warwick, Sarissa Biomedical 
(Warwick, UK) have developed SMARTchip, an amperometric biosensor with the potential 
to detect purine nucleosides from whole, unprocessed blood with results obtained in a time 
frame in the order of minutes. This in turn opens the possibility of purine nucleosides being a 
clinically useful biomarker. Details of sensor mechanism of action, development and 
validation are discussed later.  
 
Encouraging results were obtained using an earlier developmental version of SMARTchip 
(SMARTcap) (6). This study identified significant purine nucleoside changes in peripheral 
arterial blood samples in line with cerebral ischaemia secondary to interruption and 
subsequent restoration of carotid blood flow in patients undergoing carotid endarterectomy 
with local anaesthetic. To build on these results a series of prospective observational cohort 
studies using SMARTchip were designed to assess purine nucleoside use in a wider range of 
clinical scenarios where ischaemia and the risks associated with ischaemia are a necessary 
intraoperative step or ischaemic complications as a result of disease process, intervention or 






2. Rationale for choice of current study 
 
2.1 Phase one - Systemic Sampling 
2.1.1 General Anaesthetic Carotid Endarterectomy 
Neurological complications of Carotid endarterectomy (CEA) caused by embolism of plaque 
material from the operative site or cerebral hypoperfusion during carotid cross clamping 
combined with inadequate collateral perfusion can cause significant neurological morbidity 
(118). Procedural risk of stroke has been a source of much debate, currently it is quoted at 
around 2% (84, 119, 120). Many preoperative and intraoperative cerebral protection 
strategies have been postulated in an attempt to identify those at risk of hypoperfusion 
cerebral injury. Pre-operatively, radiological assessment of collateral flow can be undertaken 
by computer tomography (CT) or magnetic resonance (MR) angiography. An incomplete 
circle of Willis is associated with increased incidence of neurological events (121, 122) 
however sensitivity of radiological imaging drops significantly as vessels decrease in size 
(123). Intra operatively, local anaesthetic affords clinicians the luxury of direct neurological 
assessment of the awake patient (124), decline in neurological functioning can be easily 
identified at an early stage by assessing response to commands or questions, therefore whilst 
a purine nucleoside concentration change in local anaesthetic (LA) CEA is of interest, its 
usefulness in clinical assessment of cerebral adenosine triphosphate (ATP) metabolism is 
limited.  
 
Local anaesthetic procedures are not desirable in every patient. The requirement for the 
patient to lie still with the neck extended and rotated away from the surgeon for a prolonged 
period of time can be challenging and this can be compounded by challenging soft tissue, 
neurological or arterial anatomy. In these situations, general anaesthetic (GA) is preferable. 
Many mechanisms of monitoring cerebral perfusion during GA exist currently including 
electroencephalography (EEG), somatosensory and motor evoked potentials (SSEP), 
transcranial Doppler (TcD), carotid stump pressure monitoring, and cerebral oximetry. None 
of these modalities have been universally accepted or validated in clinical practice as all have 




The gold standard method to ensure adequate ipsilateral cerebral blood flow intraoperatively 
is insertion of a temporary shunt. Shunting involves the use of a plastic tube inserted into 
distal and proximal ends of the carotid arteriotomy during the endarterectomy and patch (if 
used) phase of CEA procedures. The shunt is inserted after opening the carotid artery and 
removed prior to completion of closure of the vessel. Shunts allows ipsilateral carotid blood 
flow to be maintained throughout the procedure with only very short duration of interruption 
of ipsilateral blood flow during shunt insertion and removal. Some would advocate routine 
shunting in all patients undergoing GA CEA to negate risk of hypoperfusion-ischaemia 
injury. However, the intraoperative use of shunts is not without risk of air or plaque 
embolism and vessel wall endothelial trauma which may cause neurological morbidity in the 
perioperative period. Published large scale pooled and meta-analyses have failed to clearly 
advocate superiority, in terms of reduction in neurological events, of either selective (based 
on pre or intra operative assessment of ipsilateral cerebral perfusion), routine or never 
shunting strategies (85, 125, 126). This may indicate a proportion of shunts inserted are 
unnecessary, exposing patients to risk (126). SMARTchip potentially may offer a rapid, 
simple intraoperative test to identify evolving cerebral ischaemia during GA CEA and thus 
those patients at risk of neurologic injury due to hypoperfusion and thus require shunt 
insertion. 
 
2.1.2 Abdominal Aortic Aneurysm: open and endovascular repair 
Abdominal aortic aneurysm (AAA) repair is defined as major plus surgery and is undertaken 
in high risk a population of patients. As such, mortality rates are approximately 4% following 
elective open surgical repair (OSR) and 1% following endovascular aneurysm repair (EVAR) 
(127). Mortality rates following repair after rupture are significantly higher. In addition to 
this, there is potential for significant complications and thus morbidity in the perioperative 
period.  
 
During OSR cross clamping of the infra-renal aorta is mandatory in order for graft 
implantation. This clamping renders the pelvis and lower limbs ischaemic as well as 
interruption of inflow to the descending and sigmoid colon via the inferior mesenteric artery 
and inferior and middle rectal arteries for a period of time until completion of graft 
implantation. Whilst the inferior mesenteric artery is universally sacrificed during aneurysm 
repair and collateral flow via the marginal artery is relied upon, ischaemic complications in 
the form of renal, gut or lower limb ischaemia represent a significant proportion of surgical 
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complications necessitating unplanned interventions or re-interventions (128, 129) either 
during the index procedure or in the perioperative period. This may be due to loss of a native 
vessel with inadequate collateral supply, thrombosis-in-situ of the graft or native vessels or 
embolism to distal vessels on reperfusion. Whilst there is no formal vascular “clamping” in a 
traditional surgical sense during EVAR, ischaemic complications are well recognised. 
Endograft position may be suboptimal and inadvertently completely occlude or shutter renal 
or visceral vessels (130-132). There is also potential for displacement or kinking of 
endografts resulting in thrombo-embolic complications there is potential for this as early or 
late phenomena (133). There is also repeated short duration arterial occlusion during 
endograft deployment and moulding. Ischaemia of lower limbs intra-operatively due to 
insertion of large calibre (16f or greater) introducers into the common femoral vessels has 
also been reported (134).  
 
Significant biochemical stress response to AAA surgery has been demonstrated in the form of 
perioperative increases in inflammatory cytokines, glucocorticoids, cortisol and oxygen free 
radicals which may represent a degree of ischaemia-reperfusion injury (135, 136) and 
increases in purine nucleosides have been identified in serum pre-operatively in patients 
awaiting AAA repair when compared to age and sex matched controls without AAA (137, 
138). Perioperative changes in purine nucleosides as a marker of intraoperative ischaemic 
cellular stress, including differences between OSR and EVAR, or as potential markers of 
ischaemic complications of aneurysm surgery have not been studied.  
 
2.1.3 Peripheral arterial disease and critical limb ischaemia  
Peripheral arterial disease (PAD) is thought to affect more than 200 million people 
worldwide (139). A significant proportion (between 20 and 50%) of patients with PAD are 
asymptomatic or symptoms are masked by concomitant disease (cardio-respiratory or 
musculoskeletal) affecting their ability to walk (140, 141). Classical symptoms of intermittent 
claudication (IC) such as reproducible, consistent exercise induced lower limb discomfort 
and fatigue are only present in a small number of patients, diagnosis can be confounded by 
non-arterial lower limb pain such as neuropathy, arthritis of the spine, hip or knee, vasculitis 
or venous insufficiency (142). Development of critical limb threatening ischaemia (CLTI) 
with either rest pain, night pain or development of ischaemic ulcers or gangrene has been 
reported at 7.5% of patients within one year of referral to vascular services with intermittent 
claudication (IC) and has an annual incidence 0.35%  (143, 144).   
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Untreated, PAD can result in significant morbidity due to lifestyle limiting claudication, limb 
loss or ultimately death (145). Patients with PAD require aggressive lifestyle adjustment and 
medical management of co-morbidities including cardiovascular risk factors to prevent 
disease progression (146). Despite this literature cites up to 25% of patients with IC will 
progress to need intervention with a primary amputation rate of between 40 and 70% at five 
years after diagnosis (147-149). Decision making around when it is most appropriate to 
intervene can be challenging for clinicians. Both surgical and radiological intervention are 
not without risk, with potential to worsen ischaemia and/or accelerate the necessity for 
amputation (150, 151). As such, intervention is commonly reserved for those with CLTI 
(152).  
 
Historic work has identified ongoing abnormal, elevated purine release in venous samples 
from chronically ischaemic tissue (59, 98) and specifically in PAD patients during exercise, 
compared against non-PAD controls. No work has been undertaken to assess the correlation 
of PAD severity and/or disease progression and purine nucleosides or effect of 
revascularisation on purine release from chronically ischaemic tissue. These factors must also 
be correlated with clinical outcomes.  
 
2.1.4 Microvascular free tissue transfer flap  
Free tissue transfer flap procedures, only possible with the advent of microvascular 
anastomotic techniques, have greatly expanded reconstructive options available to surgeons 
and patients. Common clinical applications include following major traumatic injury and 
radical oncological resection to provide soft tissue coverage of deep structures, restore 
anatomical form and in some cases restore function (153). Transplantation of tissue based 
around its own vascular pedicle by definition requires a primary period of ischaemia between 
excision and implantation. Prolonged primary ischaemia has been postulated to play a role in 
ischaemia-reperfusion injury of the flap and poorer long-term outcomes i.e. flap survival 
(154-156). A secondary ischaemic insult to the flap can occur postoperatively, this can be 
caused by arterial or venous occlusion and again may threaten viability of the flap in part or 
as a whole (157).  
 
Overall rates of flap success are excellent, but identification of a potentially ischaemic flap 
relies on clinical assessment. This can be difficult and confounded by clinician experience, 
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temperature, anaemia, use of coloured skin preparation solutions and availability of 
equipment such as Doppler ultrasound. Identification of an ischaemic flap is especially 
difficult if a significant proportion of the flap is positioned subcutaneously under native skin 
(158, 159). A peripheral serum biomarker of evolving flap ischaemia may be of clinical use 
where there is clinical uncertainty regarding perfusion of a flap intra or post-operatively.  
Significant elevation in purine nucleosides have previously been identified in interstitial fluid 
samples and in tissue biopsies during primary flap ischaemia and initial reperfusion (1hr post 
revascularisation) (76, 160).  
 
2.1.5 Renal transplantation 
In 2018, 3272 renal-only transplants were performed in the UK. Despite this only 61% of 
patients receive a transplant within three years of being added to the waiting list (161). Whilst 
five year transplant survival rates for living and deceased donors are 93 and 86% respectively 
the shortage of donated organs compared to potential recipients highlights the need to ensure 
every possible measure is taken to maintain and improve function and survival rates in the 
long term.  
 
As with free tissue transfer flaps a period of renal ischaemia during transplantation is 
unavoidable. This occurs in the kidney between completion of nephrectomy in the donor and 
completion of arterial anastomoses in the recipient. This time can vary significantly 
dependent on relative locations of donor and recipient (i.e. living related/unrelated donors 
where nephrectomy and transplant can take place almost in parallel vs deceased donors where 
significant time may be needed for transport), type of donor (the need for cross-matching and 
tissue typing in deceased donors), theatre availability and technical and anatomic challenges 
intraoperatively (162). Investigation into the effect of ischaemia on transplant outcomes  has 
been extensively studied (163-166). This has led to development of protocols to minimize 
ischaemic time that include therapeutic hypothermia (packing the kidney in ice) and 
dedicated preservative solutions (167) all aimed at decreasing ischaemia stress to the kidney 
resulting in improved function and longevity. 
 
Studies in both animal models and human transplanted kidneys have demonstrated rises in 
purine nucleosides in renal vein samples during transplantation (104-106). This has then been 
extrapolated to potentially be a marker of renal ATP stores failing to meet metabolic demand 
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despite measures taken to reduce energy expenditure during transplantation. This purine rise 
has yet to be correlated to function or survival. 
 
The aim of these studies is to replicate the published LA CEA study and investigate changes 
in systemic (arterial) purine nucleosides in response to iatrogenic ischaemia in populations of 
patients undergoing surgery to provide proof-of-concept data that purine nucleosides are of 
clinical value in situations where an early biomarker of ischaemia would potentially be of 
clinical interest.  
 
2.1.6 Mixed “non-ischaemic” controls   
Given all of the studies described above are to be undertaken in populations of patients 
undergoing procedures where periods of tissue ischaemia are a necessity. Participants 
undergoing a variety of general anaesthetic procedures without an ischaemic component were 
recruited to act as “non-ischaemic” controls in order to investigate changes in peripheral 
serum purine concentrations related to physiological stress associated with surgery without 
superimposed ischaemia.  
 
2.2 Phase two: Local Sampling 
In addition to, and based on the results of, the first phase of SMARTchip studies, a second 
phase of studies was designed to investigate variation in purine nucleoside concentrations 
locally within a given ischaemic area. As SMARTchip has the capability to determine purine 
nucleoside concentrations from extremely small sample volumes there is potential for the use 
of capillary blood, obtained via a finger prick (or equivalent) to provide adequate blood 
volumes for analysis. The advantage of this is that it extends the applicability of SMARTchip 
beyond that where a facility for venous blood sampling exists. Capillary blood sampling is 
easily achieved in community and pre-hospital settings. It is regularly used in the monitoring 
of blood glucose levels in diabetic patients and requires minimal training to perform. Clearly 
direct sampling for cerebral, aortic or renal ischaemia is not practical or possible, therefore, 
these studies focused on limb ischaemia as samples could be obtained easily directly via toe 






2.2.1 Acute Limb Ischaemia  
Acute limb ischaemia (ALI) has been defined internationally as “any sudden decrease in limb 
perfusion causing a potential threat to limb viability” can be caused by embolus, situ 
thrombosis or trauma and is a surgical emergency (168). It remains a common presentation to 
secondary care with an incidence of 10-16 per 100 000 population per annum. Mortality rates 
of 9-22% have been reported with three month amputation free survival of only 59% (169). 
Timely recognition and prompt intervention are paramount to avoiding sequelae of ischaemia 
such as reperfusion injury secondary to free radical formation, compartment syndrome, limb 
loss and death (170).  
 
Traditionally ALI was diagnosed by the presence of “the six p’s” – pain, pallor, perishing 
cold, pulselessness, paraesthesia and paralysis. In clinical practice this sextet of signs and 
symptoms can be present or absent in varying degrees and primary assessment may often be 
carried out by non-vascular specialists. This may result in subtle changes in a limb not being 
appreciated (111, 171). Palpation of peripheral pulses and Doppler ultrasound evaluation is 
often performed and interpreted poorly with significant inter-observer variability, potentially 
providing false reassurance (113). This can lead to diagnostic uncertainty and delay.  In the 
current hub-spoke vascular network design, a patient with suspected ALI may present to 
services away from vascular specialists. Acute ischaemia leading to limb loss is a significant 
cause of litigation against the NHS with delay in diagnosis stated as a significant contributory 
factor in actions reported by the NHS litigation authority (111).  
 
Previous work (99) has identified elevation in purine nucleosides in venous washout 
following a period of acute limb ischaemia. A simple test of peripheral blood marker to 
identify patients suspected of having ALI would be of use to non-vascular specialists such as 
general practitioners (GPs), allied healthcare professionals such as paramedics and 
emergency department clinicians in order to expedite appropriate triage and referral to 
specialist secondary services which may in turn lead to improved patient outcomes in terms 
of morbidity and mortality associated with ALI. This study investigates the use of purine 






2.2.2 PAD & Critical Limb Ischaemia  
In a similar fashion to the phase one systemic sampling of patients with CLTI, this study aims 
to characterise perioperative and medium-term changes in serum purine concentrations in 
patients undergoing lower limb revascularisation. 
 
The key difference between this and the previous study is blood sampling will be directly 
from the affected limb via toe prick samples. As previously stated, elevation in purine 
nucleosides has been documented in samples obtained from the popliteal vein in PAD 
patients at rest and whilst undertaking exercise (98). The pattern of purine release following 
definitive revascularisation has not been studied although logic would lead to the hypothesis 
that once adequate flow to meet oxygen demand has been restored purine metabolism should 
cease and mechanisms for normal cellular energy production would be restored. 
 
The aim of this study is to evaluate local purine changes within critically ischaemic limbs and 
the effect of surgical revascularisation. In comparison to this study and the critical limb 
ischaemia arm of the dynamic control group in this arm the range of surgical procedures 
considered eligible has been narrowed significantly to include only femero-popliteal, femero-
distal and popliteal distal bypass grafts. The effect of this is homogenisation of the study 
cohort compared to the systemic CLTI study and offers the ability to study purine nucleoside 
changes in a single limb in isolation. 
 
2.3 Non-surgical populations 
2.3.1 Traumatic brain injury 
Approximately 1.4 million people attend hospital following head injury in the UK every year 
(172). Outcomes following traumatic brain injury (TBI) remain poor (173). Primary injury 
triggers a number of secondary inflammatory cascades that are yet to be fully understood. 
These include pro-inflammatory cytokine release, formation of oxygen free radicals and 
excitotoxin release (174-176). This can lead to blood brain barrier (BBB) dysfunction, 
cellular swelling, vasogenic and cytotoxic cerebral oedema and neuronal apoptosis and 
necrosis. These pathological processes create phenomena of either localized or generalized 
cerebral hypoxia and ischaemia. Untreated, both hypoxia and ischaemia have been shown to 
be associated with poorer neurological outcomes following TBI (177).  
 
 53 
Whilst this cohort of patients differs significantly in terms of diagnosis and potential 
intervention strategies from the other study cohorts. The mechanism of cerebral injury is 
similar to both carotid endarterectomy and previous studies in patients suffering stroke with 
cerebral ischaemia a predominant factor in neurological injury, thus it was felt that there is 
potential to deploy purine nucleosides in the evaluation of patients who have suffered TBI.  
 
Given that presentation to the emergency department following a fall is common (178), 
significant head injury following a fall is relatively uncommon (179). The consequences of 
unidentified head injury can be catastrophic. Increasing population age (180) combined with 
increasing use of antiplatelet and anticoagulation agents (181) provides a “perfect storm” 
scenario whereby patients at increased risk of falls are also at increased risk of intra cranial 
bleeding. In an emergency department (ED) setting the most effective mechanism for 
diagnosis of TBI is CT imaging of the head. Anecdotal evidence suggests a significant 
proportion of CT imaging requested following suspected head trauma do not reveal any 
intracranial injury (unpublished observations). It would seem logical these scans have been 
requested based on mechanism of injury and bleeding risk factors rather than clinical signs 
and symptoms of TBI.  
 
Numerous biomarkers have been studied in an attempt to diagnose and predict severity and/or 
outcomes following TBI. S100 calcium binding protein b and glial fibrillary acidic protein 
have been shown to correlate well with acute traumatic radiological lesions and clinical 
outcomes (182-184). Expansion of their use has been limited in clinical practice by the need 
for specialist processing techniques meaning analysis times are relatively prolonged and 
prohibitively expensive. Purine nucleosides have also previously been studied in the context 
of TBI. Significant transient increases in adenosine, inosine and hypoxanthine have been 
identified in experimental models and in patients with TBI (185, 186).   
 
Potential remains for a simple, reliable test to identify those at risk of TBI following head 
trauma. Pre-hospital point-of-care testing to best triage patients appropriately or ED point of 
care testing to guide further investigation and management are both potential applications of 
SMARTchip. This study was designed to assess peripheral serum adenosine changes using 





3. Methods 1 – Design and validation of the biosensor 
 
3.1 Amperometric Biosensors 
There is much interest in the field of biosensors and their application in clinical medicine 
(187). Their role focuses on the rapid recognition of a given substance (e.g. physiological 
metabolite or drug) that can allow snapshot measurements or continuous monitoring in vivo. 
An ideal biosensor can respond continuously, and reproducibly over wide concentrations of a 
given analyte. The analyte should also be able to be detected in a variety of biological fluids 
such as blood, plasma, sweat, cerebrospinal fluid or saliva (188, 189). Sensor activity must be 
robust with the ability to be maintain sensitivity over time, pH and changes in temperature 
(190). Increasing automation in production has allowed miniaturisation of components and 
production of sensors sufficiently robust to be used outside of the controlled environment of 
research laboratories. This combined with their inherent ability to provide rapid results 
increases their usefulness in clinical medicine. 
 
3.1.1 Mechanism of action 
An electrochemical biosensor allows recognition of a biological compound and conversion, 
via an electrode transducer, into an electrical signal that can then be interpreted as a 
decimalised number. Two common types of electrochemical biosensors are amperometric 
and potentiostatic (188).  
 
Amperometric biosensors use oxidation of an electroactive substrate, namely hydrogen 
peroxide (H2O2). Oxidative enzymes specific to the analyte in question are encapsulated in a 
matrix, forming a thin layer, surrounding a working electrode. The reaction catalysed by the 
enzyme produces H2O2. This H2O2 is then oxidised by initiating and maintaining a potential 
between the working electrode and a reference electrode. The current generated will increase 
with increasing concentrations of the substrate as more H2O2 is produced (Figure 2: oxidation 
of a substrate to liberate H2O2). This current can be converted into a numerical value with 
relation to a reference electrode via a transducer and appropriate software. Selection of the 
working electrode is dependent on its reactivity to H2O2 commonly used working electrodes 
are platinum (Pt), gold (Au), carbon and metalized carbon (190). Reference electrodes are 























In order for oxidation of H2O2 to be detected oxidative enzymes must be held locally to the 
surface of the working electrode. This occurs due to trapping of the enzymes in a biologically 
inert matrix applied to the surface of the electrode.  Various mechanisms have been attempted 
to achieve this such as adsorption, solvent casting, covalent binding and 
electropolymerisation (192). Sol-gel matrices have achieved much attention in recent times, 
this is a process whereby small (nanometer sized) inorganic particles are suspended in a 
liquid then deposited onto the desired surface (the electrode). They have increased in 
popularity due to their tuneable porosity (the ability to manipulate the matrix structure to 
limit particle passage through its structure), thermal and chemical stability and 
biocompatibility (192, 193). Commonly used sol-gels include silica and titanium (192, 194). 
 
Another mechanism for achieving reliable and reproducible sol-gels is via electrodeposition 
of pyrrole derivatives (195, 196). An electropolymerisable monomer solution containing a 
known quantity of a desired enzyme is oxidised via a current generated at the electrode 
surface. This leads to precipitation and polymerisation of the solution to create layers of 
matrix, entrapping enzymes on the electrode surface (195). Repeated current cycling leads 
thicker layers of matrix deposited. This is advantageous as additional enzyme is available to 
catalyse substrate. Although it has been shown that large increases in matrix depth may cause 
the matrix to delaminate from the electrode and can cause a decrease in signal due to 
increasing distance of the reaction with H2O2 from the electrode surface (190).  
 
3.1.2 Interfering actions and reactions 
In order to create a sensor of sufficient sensitivity a relatively high anodic potential can be 
needed (>0.6V) (46), This in turn can lead to interference. In vivo electroactive substances of 
a similar molecular weight to the substrate in question such as ascorbic acid, uric acid and 
paracetamol. These have potential to cause interference as they may be oxidised at the 
working potential of the biosensor, thus amplifying the signal from the sensor that will lead 
to overestimation of the result obtained. Biofouling and electrode passivation are further 
potential sources of inaccurate results.  The concept of biofouling refers to large molecules 
such as cellular debris, proteins or whole cells as well as naturally occurring reactions within 
biological fluid (such as coagulation in blood) that impede or prevent analyte diffusion to the 
biosensor surface. Passivation occurs when small molecules adhere to the sensor surface, 
decreasing its active surface area. Both will lead a decrease in in sensor reaction to a given 
concentration of analyte (197). 
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Artificial electron mediators are now used to lower the working potential required for 
reactivity to occur thus negating the effect of interfering substances (46, 198). An additional 
benefit of electron mediators is the biosensor is no longer oxygen dependant (197, 198) and 
therefore sensitivity is maintained where oxygen tension is decreased. An ideal electron 
mediator allows direct electron transfer whilst not altering sensor response time and remain 
chemically stable in both oxidised and reduced forms (188). Commonly used electron 
mediators belong to the family of ferrocyanides (197) such as Prussian Blue (PB) or its 
analogues; palladium hexacyanoferrate, chromium hexacyanoferrate and cupric 
hexacyanoferrate as they have strong electrocatalytic action towards H2O2, and exhibit a poor 
response to coexisting oxidizable substances (199).  
 
3.2 Development of the Purine Specific Biosensors 
An amperometric biosensor (SMARTchip, Sarissa biomedical, Coventry, UK) was developed 
and refined over a number of years to be sensitive specifically to purine nucleosides formed 
following the metabolism of adenosine triphosphate (ATP). These are namely adenosine, 
inosine and hypoxanthine. SMARTchip has the ability to analyse samples of unprocessed 
whole blood in real time with the aim of developing a test that can be used at point-of-care in 
a clinical environment.  
 
3.2.1 Design and Manufacture 
The current biosensor utilises Ruthenium Purple (RP), another analogue of PB, as an electron 
mediator (46) Unlike PB, RP’s electrochemical properties are unaffected by cations 
commonly found in vivo such as sodium (Na+), hydrogen (H+), calcium (Ca2+) and 
magnesium (Mg2+) (6). The biosensor is then able to be reliably used as a sensor in Na+ based 
physiological fluids in vivo. 
 
Firstly, a gold (Au) electrode (to become the working electrode) has to be coated with RP as 
an electron mediator. The electrode is pre-treated in 1M sulfuric acid and polarised between 0 
and 1.5V at a sweep rate of 50mV/s to form a gold oxide (Au2O3) coating. The electrode is 
then cycled at 0.1V to 1.0V at a rate of 50mV/s in a mixture of iron chloride (FeCl3), 
potassium hexacyanoruthenate (K4Ru(CN)6) and potassium chloride (KCl). Finally, RP is 
electrodeposited onto the pre-treated gold electrode from an acidic (pH 2) solution of 
ruthenium chloride (RuCl3) in cycles at the same voltages and sweep rate. At approximately 
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30 cycles, two well defined redox peaks are noted with further cycles decreasing the peak 
current indicating complete coverage of the Au with RP (46).  
 
The second step in sensor formation is deposition of the sol-gel, enzyme containing matrix 
onto the pre-treated electrode. To form the solution; acidic solutions of hydrolysed silanes 
(inorganic compounds of silicon and hydrogen such as tetramethoxysilane and (3-
aminopropyl) trimethoxysilane) are formed then added to a buffer solution to partially 
neutralise the pH (47). The enzymes; adenosine deaminase, nucleoside phosphorylase and 
xanthine oxidase (1U of each) are added individually to 10µ/l of the neutralised solution 
(198). The working and null electrodes are introduced to each of these enzyme containing 
solutions in turn and polarised to between -900 and -1200 mV for between ten and 40 
seconds (46). This leads to precipitation and polymerisation of the solution to form a 
uniform, thin layer of gel matrix entrapping enzymes around the working electrode. Null 
sensors can also be produced by replicating the process in solutions not containing enzyme. 
Sensors are then washed in pure water to remove any unbound enzyme (46). 
 
Current SMARTchip design incorporates four sensors per chip. As a blood sample is 
introduced onto the sensor it is polarised for 180 seconds. The values for the final ten seconds 
for each electrode are averaged to give an integer for each active electrode. Raw results give 
a total of four readings (one for each sensor), these can then be averaged to provide a single 
final value.  
 
3.3 Validation of sensor design 
Details of sensor design, development and validation of its performance have been published 
in detail previously (6, 46, 47, 198). 
 
3.3.1 Sensitivity and selectivity 
Performance of the biosensor was analysed in a flow system for 1 hour with 40µM of ATP in 
a phosphate buffer (pH 7.4, NaCl 0.1M). Response of the sensor was linear from 0.3-80µM 
ATP, after which response plateaued resulting in sensitivity to ATP of 126nAµM-1cm-2. 
Response to hypoxanthine was analysed by adding increasing concentrations of hypoxanthine 
to phosphate buffer. Response was linear from 0.2-40µM hypoxanthine with a sensitivity of 
334nAµM-1cm-2.  
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3.3.2 Sensitivity in the presence of confounders 
Sensor performance was tested in the presence of potentially interfering substances found in 
vivo (Substances with a similar molecular weight to ATP that may competitively inhibit 
sensor performance). To test sensitivity to ATP, buffer solutions were prepared with 
concentrations of 40µM ascorbic acid, dopamine and paracetamol. No interfering signals 
were detected on testing with addition of 40µM ATP at -50mV. Sensitivity to 40µM 
hypoxanthine was tested in samples prepared with addition of 100µM 5HT, 100µM ascorbic 
acid, 1mM paracetamol and 1mM uric acid, again no interfering signals were detected. These 
results infer the use of RP as an electron mediator allow sensitivity and selectivity of the 
biosensor to be active at sufficiently low potentials as not to be affected by physiological 
substances or drugs in vivo. 
 
Response of the sensor in changing oxygen saturations was achieved by testing performance 
in saline solutions firstly saturated with 95%O2 and 5% CO2 and secondly with 95% N2 and 
5% CO2 (47). The reduction in current in total absence of O2 was 3.2±1.3% of the total 
response meaning sufficient responses were maintained in order for SMARTchip to function 
in low oxygen (O2) scenarios such as ischaemia. Such low oxygen partial pressures will not 
be encountered in vivo. 
 
3.3.3 Effect of pH on sensor characteristics 
Significant variation in pH may be encountered in vivo during ischaemia as acid-base 
homeostatic mechanisms become overwhelmed. The biosensor could be affected by pH 
disturbance either via the electron mediator or by denaturation of the entrapped enzymes. 
Sensitivity of response of the biosensors to 10µM hypoxanthine and 10µM ATP respectively 
was tested at increasing pH of the buffer solution from 6.8 to 8.0 Response was stable 
between 7.0 and 8.0. pH outside of this range is extremely unlikely to be encountered in 
samples of physiological fluids (46). 
 
3.3.4 Longevity of sensor 
Another source of potential confounding results would be sensor degradation due to 
instability of the sol-gel or decreasing enzymatic activity over time. This was found not to be 
the case, 95% sensitivity was maintained after three months of dry storage at 4oC (198).  
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3.3.5 Sensor performance in blood 
The developed biosensor was validated for use in physiological fluids by adding known 
quantities of purines to samples of fresh, unprocessed whole blood and spun-down plasma. 
Recovery percentages were 54% and 88% for the whole blood and plasma respectively (6). It 
is well known that purines nucleosides are inherently unstable in whole blood with a half-life 
of seconds (21). The discrepancy between the values is due to uptake of purines by 
erythrocytes to be re-phosphorylated to ATP and/or degradation to urate/uric acid by 
enzymes on the cell membrane of red blood cells (200).  
 
3.4 Sampling procedure and result validation 
3.4.1 Sampling technique 
SMARTchip is designed as a single use testing mechanism. Each measurement of purine 
nucleosides requires an individual SMARTchip to be calibrated prior to adding the blood 
sample to be analysed. First a buffer solution containing 10µM adenosine is added to the chip 
ensuring the whole of the sensor area is covered. A polarising cycle is run in order to 
calibrate each individual SMARTchip against a known concentration of purine. A null 
washing buffer is then added and polarised to clear the sensor of the adenosine buffer. 
Finally, the blood sample for analysis can be deposited onto the sensor surface. The volume 
of blood required to cover all four sensors is approximately 10-15µl.  
 
Dependant on sampling method, transfer of blood from site of sampling to chip can be 
achieved in various ways. Arterial line blood samples, blood can be directly dropped onto the 
chip from a syringe. If using capillary blood samples, blood can be transferred via a 
micropipette and dropped onto the chip or dropped directly from the site of sampling if 
possible.  
 
After the analysis polarising cycle is run specialist software can interpret the differences in 
current generated between the adenosine buffer and the blood sample and present this as a 






3.4.2 Pitfalls of sampling 
After production SMARTchips are dried and stored at 4oC. On addition of the first adenosine 
buffer adequate time must be allowed for rehydration of the biosensor, this need only be in 
the order of seconds. This can be achieved by adding the first buffer solution to the chip prior 
to entering chip and patient details into the analysis software, time taken to complete this is 
more than adequate for sensor rehydration. 
 
Second, the biosensors on the chip are unprotected and physical contact to the sensor can 
damage the sensor surface meaning results may not be generated or results produced are 
unreliable. Care must be taken to avoid any contact with the sensor surface, buffer solutions 
and samples for analysis can be dropped from a small height above the sensor, avoiding 
formation of bubbles within the fluid on the sensor surface. Bubbling appears to only occur 
with blood samples and is likely due to its higher viscosity than the buffer solution. Bubbles 
within the analysis sample can have a confounding effect on results as there is the possibility 
of the sensor surface not being covered, i.e. contained within a bubble, despite seemingly 
complete sensor coverage.  
 
3.4.3 Validation of individual results  
Currently, each individual result requires manually validating before results can be 
interpreted. This is a three-step process. First, the analysis software produces a faradaic 
charging curve of the current against time for both of the active sensors and both of the null 
sensors during analysis and the final current readings should be between -20 and -30nA. 
Curves should be smooth, with little deviation. Samples exhibiting unexpected curves or 
positive currents were rejected. The second stage involves reviewing the raw data. Each 
sensor calibration factor must be between -1 and -10 µM/nA. This indicates the SMARTchip 
is calibrated properly and is able to give a valid result. Finally, the sample difference, i.e. the 
difference in current between the null and active sensor should always be a negative integer, 
this can be of any value. Only if these three conditions are met can the final value obtained be 
considered valid. As previously stated, each SMARTchip contains four sensors. Results from 
each sensor have to be validated individually. The final purine concentration in µM is 
obtained from the mean of all valid results obtained from the SMARTchip.  Given each 
SMARTchip has four sensors there is a degree of latency built in and a reading can still be 
obtained if one or more of the sensors fails validation. If no valid result is obtained from any 
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of the four sensors the result must be discarded. This may mean some data points will be 





4. Methods 2 - Current study design and protocols 
 
4.1 Ethics 
Ethical approvals for the described studies were obtained from the West Midlands Research 
Ethics committee REC ref: 15/WM/0341 and 16/WM/0164. IRAS IDs: 189877 and 198854.  
 
4.2 Funding Source 
This work was funded by a National Institute for Health Research (NIHR) Invention for 
innovation (i4i) grant. Reference II-LA-0313-20002. 
 
4.3 Study design  
Phase one of this series of studies was a prospective, multi-arm, observational, cohort study 
to investigate potential clinical applicability of determination of systemic purine nucleosides 
and validate SMARTchip during ischaemia in both surgical cohorts of patients. These were 
namely: 
1- Elective carotid endarterectomy (CEA) with a general anaesthetic (GA). 
2- Elective non-cerebral surgery involving iatrogenic ischaemia including; abdominal 
aortic aneurysm (AAA) repair (both open and endovascular), renal transplantation, 
autologous free tissue transfer flap (deep inferior epigastric artery perforator (DIEP) 
flap), and surgery to treat critical limb ischaemia (dynamic controls). 
3- Elective non-vascular surgery (non-vascular controls). 
 
The second phase of study ran concurrently with phase one. This study was also an 
observational cohort study with two arms to assess purine concentration changes locally 
within the ischaemic tissue (i.e. within the lower limb) and the effect of revascularisation in 
patients undergoing: 
1- Elective total or uni-compartmental knee arthroplasty with the use of a surgical 
tourniquet, Acute limb ischaemia (ALI). 
2- Lower limb bypass surgery for critical limb threatening ischaemia (CLTI). 
A similar third study assessed purine changes in non-surgical patients with radiologically 
confirmed traumatic brain injury (TBI).  
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These studies have commonality in terms of assessment and quantification of changes in 
purine nucleosides. Each sub arm was subtly different in terms of populations of patients, site 
and duration of ischaemia and as such each arm varied in terms of the details of its design.  
 
4.4 Populations & data collection 
The numerous study groups represented heterogeneous populations of patients undergoing 
elective surgical procedures, with the exception of the patients recruited to the traumatic 
brain injury study sub arm where presentation to hospital was emergency in nature.  
 
Men and women aged 18 years and over, scheduled for elective carotid endarterectomy at 
University Hospital Coventry and Warwickshire (UHCW, Coventry) and University Hospital 
of the North Midlands (UHNM, Stoke-on-Trent), were recruited to take part in the CEA 
study. Non-vascular controls were recruited from men and women, aged 18 years and over, 
scheduled for surgery under a general anaesthetic without planned iatrogenic ischaemia at the 
same hospitals. These non-vascular controls were matched to CEA cases with respect to age 
and sex.  
 
Participants recruited to the dynamic control arms were recruited into the relevant systemic 
sampling arm from UHCW only. Patients recruited to the local sampling CLTI and ALI arms 
were recruited from UHCW only. Surgical procedures in the ALI arm were carried out at 
both UHCW and the hospital of St Cross (Rugby).  
 
Participants presenting with radiologically confirmed TBI following head injury were 
recruited from UHCW and St. Mary’s Hospital (Paddington, London).  
 
Participant recruitment and data collection in the GA CEA and non-vascular control sub 
studies was distributed between the researcher and a wider team of research nurses given 
multiple centres had been enrolled as recruiting sites. In the dynamic control, ALI, CLTI and 
TBI sub studies recruitment and data collection was performed solely by the researcher.   
 
4.5 Recruitment & consent 
Potentially eligible participants (men and women, aged 18 years and over) were identified and 
approached initially by a member of their direct healthcare team. Patients who express an 
interest in taking part were contacted by a member of the research team, who visited the 
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participants. For CEA participants, dynamic controls and local sampling CLTI participants’ 
initial approach was made upon their presentation at their pre-assessment visit, typically 
between ten days and 48 hours prior to their scheduled surgery. In some cases, potential 
participants were approached to take part in the study as hospital inpatients if their presentation 
to secondary care was as an emergency and their surgery deemed as urgent or emergency in 
nature and is expedited. In this case the initial approach was made the day prior to the 
participants’ surgery and consent taken on the day of surgery. Potential non-vascular control 
participants were approached at their pre-operative clinic, typically seven days prior to 
enrolment in the study. For logistical reasons local sampling ALI participants were initially 
contacted by telephone after their pre-operative assessment.  
 
An appropriately trained member of the research team explained the study in detail and provided 
potential participants with a comprehensive participant information sheet (PIS) specific to the 
arm of the study into which they were suitable to be enrolled. This was via post (after initial 
telephone contact) for ALI participants followed by a second telephone call once suitable time 
had been allowed to receive and study the PIS. Following this, typically the day of or day prior 
to their surgery, patients were approached by the researcher to re-check their eligibility for the 
study and to obtain informed consent for participation. Those meeting eligibility criteria and 
agreeing to participate were formally enrolled into the study and assigned a study ID number.  
 
Informed, written consent was sought from all participants prior to enrolment in the study. 
Consent was taken by a researcher who has been trained in the principles of good clinical 
practice (GCP) and the study consent procedures. Upon the participants first contact (in 
person or via telephone) with the research team, the researcher explained the study in detail 
and provide them with a comprehensive PIS specific to the study arm for which they are 
potentially eligible. Participants were encouraged to read the PIS, ask questions of the 
researcher and discuss their involvement with their friends, family and (where practical) their 
GP before deciding whether to take part. Potential participants were given a minimum of 24-
hours to consider their involvement before they were approached to give consent wherever 
possible. 
 
Potential participants were approached for informed consent when they present on the day of 
their surgery providing they meet the eligibility criteria. All participants were made aware 
that they are free withdraw their consent to participate and/or their data at any time without 
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giving a reason and that their decision to participate would not influence their current or 
future care in any respect. Participants were provided with a copy of the consent form; a 
second copy was stored with the participants’ medical notes and a third copy was stored 
securely at each site. 
 
The recruitment and consent processes for enrolment into the TBI sub-arm differed 
significantly from the other study arms. Given the emergency nature of their admission to 
hospital and time-sensitive nature of sample timing post injury. Attaining the first study 
sample took place immediately following consent, confirmation of eligibility and enrolment. 
Potentially eligible participants were identified by a member of their direct healthcare team 
upon the patient’s admission to hospital or post confirmatory radiological imaging. If 
admission was designated “major trauma” the research team was be pre-notified via in house 
systems and attended the emergency department in readiness for patient arrival with the 
major trauma team. Initial approach was directly to the participants, provided the participants 
retained the capacity to provide informed consent in line with the Mental Capacity Act (201). 
Assessment of capacity was undertaken by the researcher in real time in conjunction with the 
direct healthcare team. If the participant lacked capacity to consent, consent was sought from 
persons attending with the patient acting as a consultee. If patients attended hospital alone 
and lack capacity to consent they were not approached for recruitment. With the participants’ 
or consultees’ agreement, a research team member visited the patient as soon as possible after 
admission to assess their eligibility to participate in the study. Patients that meet the 




4.6 Inclusion and exclusion criteria  
Given the heterogeneity of the populations recruited to each sub study there were number of 
universal inclusion and exclusion criteria and some sub-study specific inclusion/exclusion 
criteria for each subgroup within the study.  
 
Systemic Sampling – inclusion criteria 
CEA: 
• Aged 18 years and over. 
• Scheduled for carotid endarterectomy.  
 
Dynamic controls 
• Aged 18 years and over. 
• Scheduled for: 
o  Aortic aneurysm repair, either open or endovascular. 
o Critical limb ischaemia surgery. Eligible procedures include femoral 
endarterectomy, axillo-(bi)femoral bypass graft, Aorto-(bi)iliac or (bi)femoral 
bypass graft, femoral-femoral crossover graft, femoral-popliteal bypass and 
femoral-distal bypass graft. 
o Renal transplantation. 
o Autologous microvascular free tissue transfer flap surgery. 
 
Non-vascular Controls 
• Aged 18 years and over. 
• Scheduled for surgery under a general anaesthetic. 
 
Traumatic brain injury  
• Aged 18 years and over. 
• Admitted to hospital with radiologically confirmed traumatic brain injury.  




Local sampling- inclusion criteria 
Acute limb ischaemia (ALI) 
• Aged 18 years and over. 
• Scheduled for elective Lower limb surgery with the use of a surgical pneumatic 
tourniquet: total knee arthroplasty or uni-compartmental knee arthroplasty.  
 
Chronic limb threatening ischaemia (CLTI) 
• Aged 18 years and over. 
• Scheduled for lower limb arterial bypass surgery; including femoral-popliteal, 




• Unable/unwilling to provide informed consent. 
• History of myocardial infarction 
• History of gout. 
• Current chemotherapy. 
• History of cerebral ischaemia (except for CEA patients). 
• History of cancer (except for free flap patients). 
 
Subgroup specific 
• Time of injury >4.5hours (TBI only). 
• History of peripheral vascular disease (ALI only). 
 
4.7 Sample size justification 
Sample size in the GA CEA and Non-vascular control studies was based on the observed 
differences identified in the previous LA CEA. Purine release in GA CEA, analysed using 
SMARTchip has not been studied previously.  
 
The dynamic control, local sampling and TBI studies were designed to extrapolate the 
findings of the LA CEA study into varying clinical situations of ischaemia and serve to 
provide pilot data for future larger scale studies. It was decided to recruit ten patients into 
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each of the five dynamic control arms of the study, the two local sampling (ALI and CLTI) 
and the TBI studies. 
 
4.8 Individual study procedures  
4.8.1 General anaesthetic carotid endarterectomy 
Surgical procedures 
CEA was performed in standard format. The use of intra operative shunting was not dictated 
by the study design and remained at the surgeons’ discretion. Method of assessment of the 
need for shunting varied between recruiting sites. One site routinely employed the use of 
transcranial Doppler ultrasound (TCD). Indication for shunting was >50% loss of middle 
cerebral artery velocity. At the second site, decisions around shunting were on a surgeon-by-
surgeon basis. Decision making tools used included incomplete circle of Willis on pre-
operative computer tomography or magnetic resonance angiography, poor back bleeding, low 
carotid stump pressures or haemodynamic instability on clamping. This variation in practice 
serves to highlight the current lack of objective evidence of methods of assessing adequacy of 
cerebral perfusion when considering carotid shunt insertion intraoperatively.  
 
Blood pressure was regulated between a systolic pressure of 110 and 180mmHg using 
glyceryl trinitrate (GTN) or metaraminol in order to maintain to maintain a mean arterial 
pressure (MAP), to give an adequate cerebral perfusion pressure. Choice of anaesthetic agent 
was at the discretion of the anaesthetist. All participants were managed in a high dependency 
unit (HDU) setting post-operatively.   
 
Sampling 
Participant flow through the GA CEA study is shown in Figure 3. Blood samples for analysis 
were obtained at baseline prior to anaesthetic, post anaesthetic but prior to commencement of 
surgery, during carotid artery exposure, at carotid cross clamp application and in ten minute 
intervals whilst the carotid clamp is applied, on clamp release (cerebral reperfusion) and 
every subsequent ten minutes until completion of the procedure, 1-hour post clamp release 
and 24-hours post clamp release. If intraoperative carotid shunting was pre-planned or 
deemed necessary intraoperatively additional blood samples were taken every ten minutes 
whilst the shunt remained in situ.  
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Pre-operative samples were capillary blood obtained via a finger prick; intraoperative 
samples for analysis were obtained via an arterial cannula, inserted into the radial artery as 
part of routine care for peri- and intra-operative blood pressure monitoring. Arterial cannulae 
are routinely removed at around 24-hours post operatively if the patient’s condition allows 
therefore the one-hour post clamp samples were obtained from this. If the arterial cannula 
was still in situ at the time of the 24-hour sample, then to avoid unnecessary finger pricks the 
sample was obtained from this. If the cannula had been removed prior to sampling a finger 








































4.8.2 Systemic sampling: dynamic controls 
Each of the five dynamic control subgroups followed a similar sampling schedule to the GA 
CEA arm, with subtle variation to accommodate differences in patients, surgical procedures 
and duration of ischaemia.  Participant flow through the “dynamic control” study is shown in 
Figures 4 & 5. 
 
Abdominal aortic aneurysm repair 
Surgical procedures 
Elective infra renal aortic aneurysm repair including tube and bifurcated grafts were carried 
out using standard techniques. Supra-renal and further proximal top clamp positions were 
excluded as were ruptured, inflammatory and mycotic aneurysms. Endovascular repair of 
infra renal aneurysms was performed following standard procedure with a surgeon and 
interventional radiologist present. Fenestrated, branched, aorto-uni-iliac and iliac branch 
devices were not eligible to be recruited. 
 
Sampling 
For all aneurysm repairs blood samples for analysis were obtained at baseline prior to 
anaesthetic and post anaesthetic but prior to commencement of surgery. For open aneurysm 
repair intraoperative blood samples were obtained during aortic exposure, post aortic cross 
clamp (most proximal clamp) application, post aortic clamp release (after completion of 
distal vascular anastomoses and thus restoration of lower limb blood flow), one-hour post 
clamp release and 24-hours post clamp release.  During EVAR intraoperative samples were 
obtained during femoral vessel exposure, during deployment of the main body of the graft 
after final graft moulding, 1-hour post completion angiogram and 24-hours post completion 
angiogram.  
 
Pre-operative samples were capillary blood obtained via a finger prick; intraoperative 
samples for analysis were obtained via an arterial cannula, inserted into the radial artery as 
part of routine care for peri- and intra-operative blood pressure monitoring. Arterial cannulae 
are routinely removed at around 24-hours post operatively if the patient’s condition allows 
therefore the 1-hour post completion samples were obtained from this. If the arterial cannula 
was still in situ at the time of the 24-hour sample, then to avoid unnecessary finger pricks the 
sample was obtained via this. If the cannula had been removed prior to sampling a finger 
prick sample was obtained.  
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Surgery for critical limb ischaemia  
For all patients undergoing surgery for critical limb ischaemia (namely arterial bypass grafts 
or endarterectomy detailed in the inclusion criteria,) procedures were carried out in line with 
surgeon preference. The study did not impose any conditions on the procedure therefore there 
was variation in specific procedure, patient anatomy, choice of bypass conduit (vein vs 
prosthetic) and individual surgeon technique. 
 
Sampling 
Blood samples for analysis were obtained at baseline prior to anaesthetic and post anaesthetic 
but prior to commencement of surgery. Intraoperative blood samples were obtained during 
inflow artery exposure, post arterial clamp (most proximal clamp) application, post clamp 
release (after completion of distal arterial anastomosis and restoration of blood flow via the 
graft), one-hour post clamp release and 24-hours post clamp release.  
 
Pre-operative samples were capillary blood obtained via a finger prick, intraoperative 
samples for analysis were obtained via an arterial cannula, inserted into the radial artery as 
part of routine care for peri- and intra-operative blood pressure monitoring. Arterial cannulae 
are routinely removed at around 24-hours post operatively if the patient’s condition allows 
therefore the one-hour post clamp samples were obtained from this. If the arterial cannula 
was still in situ at the time of the 24-hour sample, then to avoid unnecessary finger pricks the 
sample was obtained via this. If the cannula had been removed prior to sampling a finger 
prick sample was obtained. 
 
Microvascular free tissue transfer flap  
All participants recruited to this arm underwent DIEP procedures with or without 
mastectomy as part of early or delayed breast reconstruction due to breast cancer. Blood 
samples for analysis were obtained at baseline prior to anaesthetic and post anaesthetic but 
prior to commencement of surgery. Intraoperative blood samples were obtained during 
isolation of the target vascular bundle around which the flap was to be formed, post arterial 
clamp application, post clamp release (after completion of distal arterial anastomoses and 




Pre-operative samples were capillary blood obtained via a finger prick, intraoperative 
samples for analysis were obtained via an arterial cannula, inserted into the radial artery as 
part of routine care for peri- and intra-operative blood pressure monitoring. Arterial cannulae 
are routinely removed at conclusion of the procedure. Procedure duration after 
revascularisation of the flap (i.e. flap trimming, shaping and closure) dictated the mechanism 
of sampling for the one-hour post clamp samples. Sample timings were not adjusted to make 
use of the arterial cannula. If the arterial cannula was still in situ the sample was obtained 
from this if it had been removed, then a finger prick sample was taken. All 24-hour samples 




All transplant procedures were living donor (LD) transplants as these are performed on a 
largely elective basis. Recruitment of donation after circulatory death (DCD) or donation 
after brainstem death (DBD) donor transplants was not attempted due to their emergency 
nature; posing problems such as erratic procedure timing and truncated opportunity for and 
adequate consent process given clinical preoperative investigation that need to be undertaken 
by a transplant recipient pre-operatively especially when a preferable alternative (in LD 
transplants) exists.  
 
Sampling 
Blood samples for analysis were obtained at baseline prior to anaesthetic, post anaesthetic but 
prior to commencement of surgery, during iliac vessel exposure, at iliac artery cross clamp 
application, on iliac artery clamp release, one-hour post clamp release and 24-hours post 
clamp release.  
 
Unlike the other dynamic control sub-arms, arterial line placement was not universally used 
intraoperatively. Where it was placed as part of with routine care, intra operative blood 
samples were obtained via the cannula. If an arterial cannula was not inserted capillary 










Figure 4 Participant flow diagram for dynamic control recruits undergoing aortic 









Figure 5 Participant flow diagram for dynamic control recruits undergoing surgery for 





4.8.3 Non-vascular controls  
These participants were recruited from mixed pre-assessment clinics and are thus 
heterogeneous in their nature. As there were no pre-defined intraoperative “ischaemic” points 
the sampling protocol was simplified to include: pre-operative baseline, post anaesthetic but 
prior to commencement of surgery, an approximate midpoint of the procedure as designated 
by the operating surgeon and at procedure completion. It was not anticipated that any of the 
procedures would require arterial cannula insertion therefore all samples were capillary blood 
obtained via finger pricks. Participant flow through the non-vascular control study is shown 
















































4.8.4 Local sampling – acute limb ischaemia 
Surgical procedures  
Procedures included those performed under both general and spinal anaesthetic. All 
procedures were performed following standard arthroplasty technique by a single orthopaedic 
surgeon comprising of either total (TKA) or uni-compartmental (UKA) knee arthroplasty. 
Both cemented and uncemented prostheses were included. A pneumatic surgical tourniquet 
was inflated to 300 mmHg around the proximal thigh immediately after skin incision to 
completely occlude arterial inflow to the limb and render it ischaemic. This remained inflated 
throughout the procedure. Blood was not actively exsanguinated from the limb prior to 
tourniquet inflation.  
 
Sampling 
Samples were obtained directly from the operated limb pre, intra and post operatively with 
time-matched controls from capillary finger prick samples from the same subject. Due to 
availability of a single potentiostat, in order to allow accurate comparisons, the sequence of 
sampling limb sample first followed by finger sample was maintained throughout the study. 
In the operated limb pre-operative samples were obtained via capillary toe prick blood 
samples. The intra operative samples were obtained at set time points; immediately prior to 
tourniquet inflation, 20 minutes after tourniquet inflation, 40 minutes after tourniquet 
inflation and immediately post tourniquet deflation. Due to the need to maintain 
intraoperative sterility and the ability of the surgeon to manipulate the leg during prosthesis 
implantation the patients’ foot was wrapped in sterile drapes and subsequently was not 
available as an intraoperative sampling site. The intra operative samples from the operated 
leg were obtained from blood within the surgical incision at appropriate sample time-points 
and analysed immediately. A final pair of capillary samples was obtained at 1-hour post 
tourniquet deflation.  
 
4.8.5 Local sampling - critical limb ischaemia  
Surgical procedures 
Whilst this arm is very similar in nature to the dynamic control (critical limb threatening 
ischaemia) arm the breath of procedures included was narrowed to focus on a single limb. 
With regards to sample timings, at each time point samples were obtained directly from the 
operated limb with time-matched controls from capillary finger prick samples from the same 
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subject. Participant flow through the local sampling acute limb ischaemia (ALI) and chronic 
limb threatening ischaemia (CLTI) studies are shown in Figure 7. 
 
Sampling 
Pre-operative samples were obtained via capillary toe prick and finger prick blood samples.  
Intraoperative blood samples were obtained during most cranial (inflow) artery exposure, 
post arterial clamp (most proximal clamp) application, post clamp release (after completion 
of distal arterial anastomoses and restoration of blood flow via the graft). As in the ALI arm, 
due to the need to maintain intraoperative sterility and the ability of the surgeon to 
manipulate the leg during vein harvest (if necessary) and arterial anastomoses the patients’ 
foot was wrapped in sterile drapes or placed within a sterile bag. This means the foot was not 
available as an intraoperative sampling site. The intra operative samples from the operated 
leg were obtained from blood within the most distal surgical incision at appropriate sample 
time-points and analysed immediately. 
 
Post operatively samples were obtained one-hour post clamp release and 24-hours post clamp 
release, these samples, like the preoperative samples, were toe and finger prick samples. In 
this arm, one further sampling time point at the patients first surgical follow up appointment 
(approximately six weeks post operatively) was undertaken. Finger prick and toe prick 
samples were again obtained to evaluate the effect of reperfusion on chronically ischaemic 












4.8.6 Traumatic Brain Injury  
The first study sample was obtained as soon as possible after study enrolment. A second 
comparative sample was obtained at 24-hours (where possible) along with recording of 
diagnosis and any intervention to prevent or sequelae of the injury in the intervening time 
period between samples. Both samples obtained are capillary blood via finger prick. 
 
4.9 Statistical analysis plan 
4.9.1 Demographics 
Continuous demographic and procedural data was assessed for normality and presented as 
mean ± standard deviation or range as appropriate. Comparisons of means of continuous 
demographic data between groups was undertaken using independent t-tests. Chi-squared 
tests were used to analyse differences in proportions between groups of binary categorical 
demographic or procedural data where appropriate.  
 
4.9.2 Primary outcome 
The primary outcome measure in the experiments in surgical populations described here is 
intra-cohort changes in purine concentrations from baseline in response to initiation, 
continuation and resolution of ischaemia. These are presented as median±95% confidence 
intervals. A linear mixed model was fitted to analyse changes in purine nucleosides. A mixed 
model was used in order to take into account multiple related samples and assess correlation 
between repeated samples within individual patients at different sampling sites, acquired over 
time. Linear mixed models allow for both fixed and random effects on purine concentrations 
as well as making use of all available data points collected. Time variables have been 
analysed in this model as categorical rather than continuous to allow for differing profiles of 
changes in purine nucleosides  
 
In the non-surgical population (traumatic brain injury) the primary outcome is purine 
concentration on presentation to hospital. Purine concentrations are reported as median±95% 
confidence intervals. This purine concentration was compared to subsequent purine readings 
at 24-hours post admission using the Wilcoxon signed ranked test. Comparisons of purine 
concentrations between types of injury or other categorical measures were performed using 




4.9.3 Secondary outcomes 
Where applicable, differences in purine nucleoside profiles between similar cohorts of 
patients was evaluated (i.e. open AAA repair and EVAR and baseline purine concentrations 
in multiple study groups). This was performed using Mann-Whitney U test.  
 
4.9.4 Missing data  
Validation of results could only be performed post-hoc and was not available to the 
researcher at the time of sampling. The outcome of this was any results that are not valid are 
only detected after sampling was complete. Having four sensors per SMARTchip provides 
some inbuilt protection against no result being obtained. It was anticipated a proportion of 
results obtained will be completely invalid (no result from all four sensors) either due to fault 
with SMARTchip or error in sampling. As all data analysis of changes in purine nucleoside 
will be from pooled results of study subjects at any given sampling point there was tolerance 
for a small number of missing samples. Sampling points with <70% of total values available 
were excluded from subsequent analysis.  
 
Even if result validation could be achieved in real time in the experiments performed here 
many of the samples are time critical, i.e. they were taken at set intra or post-operative time 
points. Given the unstable nature of purine nucleosides in whole blood, time delay in repeat 
sampling or repeat analysis of remaining blood from initial sample would invalidate that 
result. 
 
4.9.5 Data Handling 
Screening and recruitment logs of all patients approached to take part in this study and 
enrolled in the study are held at each site. Patients that agree to participate in the study were 
assigned a unique identifier, which were used to identify all documents associated with that 
participant for the duration of the study. Eligibility, baseline health data and clinical data was 
recorded contemporaneously, by hand, in a case report form (CRF) by the researcher. 
Participant consent was recorded, in triplicate, on an informed consent form and stored 




Access to study data was restricted to members of the study team and patient identifiable data 
was restricted to those members of staff that require it for the performance of their role. 
Direct access to data was granted to authorised representatives of the Sponsor, host institution 
and the regulatory authorities for the purposes of trial-related monitoring, audits and 
inspections. 
 
Following the resolution of queries and confirmation of study close-out by the Chief 
Investigator, all essential documentation was transferred to a third-party archiving service, 
which provides suitable fire and water-resistant facilities. Patient identifiable data will be 
held for up to three years to facilitate any future food and drug administration or certification 
mark application. Anonymized data will be held for a period of 15 years. 
 
4.10 End of study 
The end of the study was defined at the date of the last patient’s last visit. 
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5. Results and analysis  
The combined studies recruited 199 participants. 190 participants underwent 191 surgical 
procedures. Nine participants in the traumatic brain injury study underwent no surgical 
procedure. In total 200 “ischaemic events” were assessed using SMARTchip. Results below 
detail each sub study individually.  
 
5.1 General anaesthetic carotid endarterectomy 
5.1.1 Demographics 
Forty participants were recruited to the general anaesthetic (GA) carotid endarterectomy 
(CEA) study. On validation of the SMARTchip data, three patients were subsequently 
excluded from the analysis due to biochemical interference at the point of sampling leading 
to erroneous readings. The results for the remaining 37 patients are presented here.  
 
Results for 28 males and nine females with a mean age of 72 (range 41-87) were analysed. 
Indications for surgery were as follows; stroke (n=20), TIA (n=15) and isolated ocular 
symptoms (n=2). Cardiovascular comorbidity as well as previous cerebrovascular disease 
was prevalent within the cohort. Full demographics of patient co-morbidity are shown in 
Table C with the demographic information from the published local anaesthetic (LA) CEA 
study for comparison. No intra operative shunt was used in 23 cases and in 14 cases were 
shunted intraoperatively. 
 
5.1.2 Operative timings 
Intra-operative timings are shown in Table D. There was no significant difference in 
procedural length between the GA shunted and GA unshunted cohorts (147±50mins vs 
143±32mins, p>0.05) the LA procedures were significantly shorter than this (95±41 mins 
p=0.09 vs shunted and p=0.Ihunted). Relative ischaemic time, defined as the period of time 
where there was interruption in ipsilateral cerebral blood flow was, as expected, significantly 
longer in the GA unshunted group than the GA shunted group (51±2 mins vs 12±8mins 










DEMOGRAPHIC N P 
GA LA 
TOTAL PARTICIPANTS 37 17  
SEX (M:F) 28:9 12:5 ns 
AGE (mean) 72 72 ns 
INDICATION FOR CEA    
STROKE 20 4 0.02 
TIA 15 7 ns 
AMAROSIS 1 3 0.06 
OCCULAR ISCHAEMIA 1 0 ns 
ASYMPTOMATIC 0 2 0.04 
COMORBIDITY    
HYPERTENSION 27 12 ns 
STROKE 25 6 0.01 
HYPERLIPIDAEMIA 18 10 ns 
DIABETES 8 0 0.03 
IHD 5 4 0.41 
PVD 2 3 ns 
SMOKING STATUS    
Current 19 4 0.04 
Ex 7 3 ns 
Never 11 7 ns 
ANTIPLATELET    
DUAL 19 6 ns 
SINGLE 18 8 ns 
NONE 0 3 0.01 
STATIN    




Table C Demographics from the recruited GA cohort. Data from the previously published 






















Table D Intra operative timings by CEA subgroup. There was no significant difference in 
total operative time between the GA CEA groups. LA CEA was significantly 
shorter (p=0.09 & 0.04 vs unshunted and shunted respectively). As expected, the 
shunted group experienced significantly shorter relative ischaemic time (p=0.001 
& 0.014 vs unshunted and LA respectively). 
 
  
 PROCEDURE GROUP. MEDIAN (CI) 
GA SHUNTED GA UNSHUNTED LA 
OPERATIVE TIME (MINUTES) 147 (97-197) 143 (121-165) 95 (54-136) 
RELATIVE ISCHAEMIC TIME 
(MINUTES) 
12 (4-20) 51 (28-74) 34 (19-49) 
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5.1.3 Intra operative blood pressure control 
Intraoperative mean arterial pressure (MAP) profiles for all groups are shown in Figure 8. In 
both the LA and GA unshunted groups intraoperative MAP varied significantly from baseline 
readings. MAP in the LA Cohort was significantly increased after application of carotid 
clamps (p=0.03) whereas MAP in the unshunted GA cohort was significantly decreased after 
anaesthesia (p=0.006) though this difference was not sustained through the remainder of the 
procedure. MAP in the GA shunted group was significantly lower than the LA group 









Figure 8 Mean arterial pressure profiles for A- GA shunted, B-GA unshunted, C-LA 
subgroups. Data is presented as median with 95% confidence limits. Sampling 
points represent pre operative baseline, post anaesthetic prior to procedure 
starting, artery exposure, clamp on and reperfusion. As each intra-operative step 
may be reached at different chronological time points (minutes) for each 
individual participant the horizontal error bars during the intra opertaive 
sampling period represent median±95% confidence limits of the chronological 
time point at which each operative stage was achieved. D In Figure A represents 
an aditional data point obtained on shunt insertion. No pre operative MAP was 
obtained for the LA subgroup as there was no GA. MAP significantly decreased 
compared to baseline in the GA unshunted cohort (P=0.03). MAP was 
significantly increased in the LA cohort on application of the carotid clamp 
compared to baseline (P=0.018). MAP in the GA shunted group was significantly 




5.1.4 Intraoperative changes in peripheral arterial purine concentrations 
There was no significant difference in baseline nucleoside concentrations between the GA 
cohorts; 3.02±1.11µM and 3.16±1.85µM in the unshunted and shunted cohorts respectively 
(p>0.05). These baseline readings were also comparable to the baseline values in the 
previously published LA cohort (2.4±1.35µM; p=0.23).  
 
There was no significant variation within either of the GA groups from baseline after 30 
minutes of carotid clamping when compared to baseline values; 2.07±0.89µM (p=0.713 
compared to baseline) and 2.4 ±3.09µM (p=0.474 compared to baseline) in the unshunted and 
shunted cohorts respectively. In addition to this there was no significant difference in purine 
concentrations between the shunted and unshunted groups at any of the sampling points. The 
profiles of purine nucleosides against time from the shunted and unshunted GA cohorts are 














Figure 9 Purine nucleoside changes in the GA shunted cohort (median & 95% CI). As each 
intra-operative step may be reached at different chronological time points 
(minutes) for each individual participant the horizontal error bars during the 
intra opertaive sampling period represent median±95% confidence limits of the 
chronological time point at which each operative stage was achieved. Compared 
to the unshunted cohort (Figure 10) D represents an additional data point on 











Figure 10 GA Unshunted cohort purine nucleosides (Median & 95% CI) presented at 
median time points whereby operative stages for sampling were reached. As 
each intra-operative step may be reached at different chronological time points 
(minutes) for each individual participant the horizontal error bars during the 
intra opertaive sampling period represent median±95% confidence limits of the 
chronological time point at which each operative stage was achieved. Observed 





The LA CEA study(6) demonstrated a peak 2.8-fold increase during carotid clamping; 2.4µM 
at baseline rising to 6.7µM during clamping. This did represent a significant increase 
compared to both GA cohorts at comparable time points, i.e. 30 minutes of carotid clamping, 
(shunted 2.4 ±3.09µM vs 6.7±3.4µM and unshunted 2.07±0.89µM vs 6.7± 3.4µM p=0.004). 
 
No significant difference was noted in the post-operative (both 1-hr and 24-hr) purine 
nucleosides between either of the GA groups and the LA group. In addition to this no 
statistically significant changes in purine nucleosides was demonstrated in differing 
anaesthetic agents used or with increasing degree of ipsilateral or presence of contralateral 
carotid stenosis.   
 
There were no reported peri-operative neurological events in either the GA or LA cohorts. 
Four patients reported transient cutaneous sensation alteration in the distribution of the great 
auricular nerve (two GA and two LA). 
 
5.1.5 Analysis 
The results of this study are directly comparable to the previous LA work (6) as the studies 
were identical except for choice of anaesthesia, however, the anticipated rise during carotid 
cross clamping was not identified.  
 
Differences in cerebral metabolism between LA and GA CEA have been identified 
previously. McLeary et al (202) analysed results of continuous jugular venous oximetry 
(SJvO2) and near infrared spectroscopy (NIRS) in patients undergoing GA or LA CEA. They 
demonstrated a smaller fall in SJvO2 in the GA cohort than the LA cohort (9% vs 13%), 
meaning cerebral oxygen consumption was decreased to a greater extent in the GA cohort. 
The NIRS measurement of oxidised cytochrome oxidase (caa3) as a proxy marker of cellular 
ischaemia showed a greater fall in the LA cohort suggesting a greater degree of tissue 
hypoxia in patients who were conscious during CEA. This is consistent with the contrasting 
findings of the LA and GA cohorts in our studies; namely cerebral metabolic rate is higher in 
patients undergoing LA CEA than GA CEA. This in turn may lead to greater cellular stress 
during LA CEA on carotid cross clamping, appreciated as detectable rise in purine 
nucleosides that is not replicated in the GA cohort. 
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The lack of any appreciable rise in purine concentration during ischaemia in the GA CEA 
cohort is at odds with previously reported measures by Weigand (80), this study did 
demonstrate a significant rise in adenosine that was measured in samples from the ipsilateral 
jugular bulb during the clamped phase of the CEA using GA. Sampling from the jugular bulb 
represents direct venous drainage of the brain (203) whereas the radial artery sampling in our 
study represents blood that has circulated through the heart twice and lungs before being 
distributed (and diluted) to the periphery. In addition, other historic studies noted differences 
in changes in purine concentrations between arterial and venous samples and between 
differing location of venous samples in the same participant (34).  
 
The direct effect of local anaesthetic agents on purine production within tissues has not been 
investigated.  Hypothetically the results obtained by Tian et al (6) could be attributed (wholly 
or in part) to changes in purine metabolism induced by local anaesthetic agents within (or 
immediately adjacent to the operative field. This would seem unlikely given the rises in 
purine nucleosides obtained directly from the main venous outflow of the brain under GA 
that was demonstrated in the Weigand study (80) however they did not report if adjuvant LA 
was used. In addition to this significant changes purine nucleosides in peripheral arterial 
samples would be unlikely to occur from the small volume of tissue (Skin, subcutaneous 
adipose and connective tissue of the neck) on which local anaesthetic agents are used.  
 
As previously stated, CEA carries an approximate 2% risk of stroke (84). Intra-operative 
carotid shunting is used to provide ongoing ipsilateral cerebral perfusion during the clamped 
phase of CEA. The use of shunts in carotid surgery remains contentious as shunting itself 
carries risk of stroke via embolization, vessel endothelial trauma or un-noticed intraoperative 
occlusion. A Cochrane review published in 2014 (85) of six studies involving 1270 patients 
and a retrospective pooled analysis of 28475 CEA procedures performed in the United States 
(125) concluded there was insufficient robust evidence to support the use of either routine or 
selective shunting. As such, there is significant variation in practice globally and selective, 
routine and no shunt use all have staunch supporters. The absence of a significant purine rises 
in the GA cohort, compared to the previous LA cohort may indicate that the decrease in 
cerebral metabolic rate afforded by general anaesthetic agents gives an element of cerebral 
protection against clamp induced cerebral hypoperfusion-ischaemia. Therefore, in a 
proportion of cases the perceived protection offered by shunting may be unnecessary and 
introduce risk than confer benefit.  
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In this study shunting remained at surgeons’ discretion. Individual surgical practice will have 
produced variation in necessity and timing of shunt insertion. In addition to this, methods for 
determination of the need for shunting varied between surgeons and between recruiting sites. 
This potentially serves to confound changes in purine nucleosides as it would be expected 
shunt insertion would attenuate ischaemic purine nucleoside production as cerebral flow is 
maintained. This is demonstrated in results obtained in patients requiring shunt insertion in 
the previously published LA study. Given rises in purine nucleosides in the LA cohort were 
appreciated prior to neurological symptoms it was not deemed appropriate to require 
surgeons to deviate from their preferred mechanisms of cerebro-protection. A lack of 
appreciable purine rise in conjunction with no perioperative neurological events could be 
interpreted as appropriate prophylactic shunt insertion based on existing selection 
mechanisms despite a lack of objective validation. There is also potential the results are a 
consequence of the relative rarity of neurological events combined with a small study 
population.  
 
Adequate cerebral perfusion pressure (CPP) to maintain normal cerebral functioning is 
defined as being between 50 and 70 mmHg (204). CPP is derived from the difference 
between MAP and intra cranial pressure (ICP). Maintenance of CPP intraoperatively during 
CEA is critical to minimise risk of ischaemic cerebral insult. In this study the assumption was 
made that all recruited patients had normal ICP as none had a history of raised ICP, prior 
neurosurgical intervention or were displaying symptoms of raised ICP at the time of CEA. 
Intraoperative MAP was maintained at a level to prevent ischaemic injury secondary to 
malperfusion, this would also be expected to prevent purine production as a result of 
hypotension rather than reduction in blood flow caused by carotid clamping. The relatively 
lower MAP readings in the GA shunted cohort may be attributable to less rigorous BP control 
given cerebral perfusion via the shunt. The relative increase in MAP in the LA study may 
also be explained by discomfort or anxiety experienced by the patient during an LA 
procedure.  
 
As the results obtained in the LA study were not replicated in the GA cohort, currently it has 
not been demonstrated that purine nucleosides can be used as an intra-operative biomarker of 
evolving or ongoing cerebral ischaemia in patients under GA. This study does offer further 
information into differences in cerebral ATP metabolism between LA and GA. It can be 
hypothesised that the lack of a rise in purine nucleosides in GA CEA may be caused by a 
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decrease in cerebral metabolic rate and loss of metabolic rate-blood flow coupling caused by 
general anaesthetic agents. 
 
5.2 Dynamic controls 
Whilst for clarity of reading these five subgroups have been defined collectively as dynamic 
controls, they actually represent separate surgical cohorts. Their commonality is all 
procedures included involve a period of intraoperative iatrogenic ischaemia. The primary 
analysis is of intra-group changes in purine concentrations at set operative time-points. 
Comparisons between these subgroups is of little value as they represent very different 
cohorts of patients undergoing different surgical procedures, with the exception of the open 
(OSR) and endovascular (EVAR) aortic aneurysm repair subgroups.  
  
5.2.1 Demographics & Surgical procedures 
Open aneurysm repair 
This sub-group consisted of nine males and one female, mean age at surgery was 66±14 
years. Mean aneurysm diameter was 5.9±1.3cm. Cardiovascular co-morbidity was prevalent 
in the cohort as was smoking, five participants were current smokers with a further two 
identifying as ex-smokers. 
 
All procedures were performed in an elective setting in a conventional transperitoneal 
approach via a midline laparotomy. Procedures included implantation of five tube grafts and 
four bifurcated grafts. One patient underwent aortic endartectomy rather than aneurysm 
repair; they have been included here as the technical steps of induction and duration of lower 
extremity ischaemia by aortic cross clamping is comparable to aneurysm repair. There was 
no significant difference in total procedure time or ischaemic time between tube and 
bifurcated grafts.  
 
EVAR 
This subgroup consisted of six males and four females, mean age at surgery was 75±11 years. 
All procedures were elective infra-renal endovascular aneurysm repairs with open access to 
the femoral vessels. Aneurysm size was 6.0±0.3cm All procedures were performed by a 
combination of a vascular surgeon and an interventional radiologist and were implanted 
within the manufacturer’s instructions for use (IFU). 
 99 
Critical limb threatening ischaemia 
This Critical limb threatening ischaemia (CLTI) group was exclusively male. Mean age at 
surgery was 64±9 years. All patients were staged clinically by the treating team using either 
the Fontaine or Rutherford peripheral arterial disease (PAD) classification scoring systems. 
Both scoring systems use an increasing numerical value to indicate increasing severity of 
PAD. A detailed breakdown of both scoring systems is shown in Table E. Whilst the 
indication for intervention was broadly the same, (intervention for critical limb ischaemia 
secondary to peripheral arterial disease) nature of arterial disease is shown in Table F, this is 
the most heterogeneous of the sub-groups in terms of pattern of disease and procedure 
undertaken. Procedures included five femoral endarterectomies, two femoral-femoral cross 
over grafts, two femoral to below knee (one popliteal and one posterior tibial) bypass grafts 
















Asymptomatic 0 I No pain  
Mild claudication 1 IIa Can complete standard 
treadmill exercise test 
Moderate 
claudication 
2 IIb Decreasing distance to 
onset of pain on testing 
Severe Claudication 3 IIb Cannot complete standard 
exercise test  
Rest pain 4 III Continuous ischaemic 
pain without tissue loss 
Minor tissue loss 5 IV Digital ulcers distal to 
metatarsal-phalangeal 
joint only 
Major tissue loss 
 
6 IV ulcers proximal to 
metatarsals or gangrene, 
























MOST SIGNIFICANT ARTERIAL DISEASE NUMBER 
CFA STENOSIS 5 
CFA OCCLUSION 1 
SFA OCCLUSION 2 
POPLITEAL OCCLUSION 1 
AORTIC OCCLUSION 1 




PROCEDURE   
COMMON FEMORAL ENDARTERECTOMY 5 
FEMORAL-FEMORAL CROSSOVER 2 
FEMORAL-POPLITEAL BYPASS 2 









Microvascular free tissue transfer 
All Procedures were deep inferior epigastric artery perforator (DIEP) flap procedures for 
breast reconstruction, therefore this cohort was exclusively female with a mean age at surgery 
of 52±5 years. One participant underwent bilateral procedures and therefore each flap was 
treated individually. The group consisted of eight mastectomy combined with immediate 
reconstruction and two delayed reconstruction following previous mastectomy. Excluding a 
history of breast cancer, the cohort was free of major co-morbidity.  
 
Transplant 
As previously stated, all transplant procedures were elective live donor renal-only 
procedures. This subgroup consisted of six males and four females, mean age at surgery 
40±11 years. Indication for transplant varied and included; IgA nephropathy (n=2), chronic 
pyelonephritis (n=2), reflux nephropathy, uromodulin disease, medullary sponge kidney, 
polycystic kidney disease, chronic pyelonephritis and glomerulosclerosis (all n=1).  This 
group were significantly younger than any other of the dynamic control cohorts (p<0.001) 
and the demographic data reflects this; significant co-morbidity, other than indication for 
transplant, was not prevalent within the subgroup.  
 





































CLTI DIEP TRANSPLANT 
TOTAL PARTICIPANTS 10 10 10 9 10 49 
TOTAL PROCEDURES 10 10 10 10 10 50 
SEX (M:F) 9:1 6:4 10:0 0:9 6:4 31:18 (63:37) 
AGE (MEAN) 66 75 64 52 40 59 
COMORBIDITY       
HYPERTENSION 5 8 5 0 4 22 (45) 
STROKE 0 1 2 0 0 3 (6) 
HYPERLIPIDAEMIA 5 6 4 0 0 15 (31) 
DIABETES 0 3 2 0 0 5 (10) 
IHD 0 5 2 0 0 7 (14) 
PVD 2 4 10 0 0 16 (33) 
OTHER 3 0 1 2 9 15 (31) 
SMOKING       
CURRENT 5 5 6 2 1 19 (39) 
EX 2 1 2 0 3 8 (16) 
NEVER 3 4 2 7 6 22 (45) 
ANTIPLATELET       
YES 7 7 7 0 1 22 (45) 
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5.2.2 Ischaemic times 
Time of ischaemia, between clamp application and restoration of flow, was available for 47 
of the 50 patients. As anticipated, duration of ischaemia varied significantly in line with 
procedure. OSR patients underwent a significantly longer period of intraoperative ischaemia 
than any other subgroup (98±14 minutes). Transplant recipients underwent the shortest 
duration of ischaemia (18±5 minutes). This transplant ischaemic time is the time between 
iliac clamp application and completion of anastomoses in the recipient, total duration of graft 
ischaemia (nephrectomy to completion of anastomoses) was not recorded. Ischaemic times 
for each subgroup are shown in Table H. 
 
5.2.3 Intra-operative purine changes 
Baseline purine and post clamp release purine readings in each of the cohorts are shown for 
reference in Table I. Each of the subgroups were found to have baseline purines within 
normal resting range (i.e. <3µM). There was no significant difference in baseline purines 
between any of the cohorts. In addition to this, the linear mixed model analysis revealed there 
was no significant variation in purine concentrations from baseline at any subsequent 
sampling point, in any of the cohorts. Perioperative purine profiles for each of the subgroups 
are presented in Figure 11(i-v). This was again true if the analysing the “dynamic control” 
cohort as a whole (n=50). 
 
As previously mentioned, the only appropriate inter-group comparisons to make are between 
open and endovascular aortic aneurysm repair groups. As with other analyses in this 
“dynamic control” study there was no significant difference between these two cohorts at any 





SUB-GROUP NUMBER ISCHAEMIC TIME 
(minutes) 
OPEN AAA 10 98±14.1 
EVAR 9 58±17.8 
CLTI 9 47±23.9 
DIEP 9 35±8.04 




Table H Ischaemic times of each dynamic control subgroup. Open aneurysm repair 






SUBGROUP NUMBER BASELINE PURINE 
µM (median±95% CI) 
POST CLAMP PURINE 
µM (median±95% CI) 
 P-VALUE 
WHOLE COHORT 50 2.32 ±0.51 1.67±0.46 0.586 
OPEN AAA 10 2.54±2.09 1.74±1.25 0.905 
EVAR 10 2.49±0.65 1.31±1.28 0.43 
CLTI 10 1.44±7.32 1.14±1.98 0.416 
DIEP 10 2.64±0.8 1.50±0.66 0.167 
TRANSPLANT 10 1.53±0.98 1.73±1.24 0.329 
 
 
Table I Summary of peri-operative purine nucleoside changes within with in each dynamic 
control group. Baseline and post clamp (reading at which largest increase was 
anticipated) readings are displayed for reference. P value given is obtained from 
linear model of all sampling points. No statistically significant change identified 











































Figure 11  Scatter plots of intra subgroup perioperative purine changes. i-open aneurysm 
repair, ii-EVAR, iii-CLTI, iv-DIEP, v-Transplant. As each intra-operative step 
may be reached at different chronological time points (minutes) for each 
individual participant the horizontal error bars during the intra opertaive 
sampling period represent median±95% confidence limits of the chronological 
time point at which each operative stage was achieved. Sampling time points 
were: Baseline, post anaesthesia, clamp application, clamp release and 1hr post 
clamp release. Baseline readings were taken prior to first case of the theatre list 
and therefore are not time-continuous with the intraoperative readings as such 
the post anaesthesia sample is marked as time point zero.  Purine results are 






The hypotheses that there would be significant perioperative purine nucleoside change in 
these surgical cohorts was based on extrapolation of the findings in the LA CEA study. As 
with the GA CEA study, results from these dynamic control studies may be confounded by 
GA. However, there may be other factors other than choice of anaesthesia that may influence 
the results obtained. 
 
Patients undergoing open aneurysm repair underwent the longest ischaemic time and had the 
largest mass of ischaemic tissue of any of the study populations. Despite this no significant 
changes in purine concentrations were noted. During EVAR there is no formal vascular 
“clamping” where flow is completely occluded for a prolonged duration. Instead, there is 
repeated, intermittent short duration (seconds only) aortic occlusion in addition to longer 
duration partial occlusions secondary to large bore (16f or greater) intra-arterial delivery 
sheaths which in theory restrict blood flow to the lower extremities for the duration of the 
procedure. It is, maybe, not unexpected that no significant purine rises were noted 
intraoperatively within participants undergoing EVAR. Ischaemic complications, though rare, 
are potentially devastating for patients and therefore are a significant issue facing clinicians 
undertaking endovascular aneurysm repair. This study was not expected to identify or have 
sufficient power to investigate ischaemic complications but form pilot data for future studies 
into purine nucleosides as markers of ischaemic complications post EVAR. Clinical need for 
a simple, reliable diagnostic adjunct to aid diagnoses remains. Whether SMARTchip can be 
used in these situations remains unclear.  
 
In comparison to other “dynamic” cohorts a microvascular free tissue transfer flap has a 
significantly smaller mass of tissue that is rendered ischaemic and the composition of that 
tissue is primarily adipose, which has a lower metabolic rate than the majority of other tissues 
studied in this series of studies. It was anticipated a purine rise would be noted on reperfusion 
whereby purine nucleosides produced during ischaemia may be detected in systemic 
circulation on reperfusion. Given the lack of rise in the GA CEA study it is unsurprising that 





During renal transplantation the aim of the study was to attempt to identify and quantify the 
effect of ischaemia in the kidney to be transplanted. It was noted that vascular control of the 
ipsilateral iliac vessels during arterial anastomosis provided a period of time within which to 
study a period of limb ischaemia. Therefore, it was anticipated there may be a “double peak” 
in purine nucleoside concentrations the first representing limb ischaemia during iliac cross 
clamping and a second, or superimposed, peak after complete restoration of blood flow 
through the transplanted kidney representing washout of nucleosides accumulated within the 
kidney during the period between nephrectomy and implantation. Whilst there was a small 
increase after clamp application 2.97±1.65µM vs 1.53±0.98µM at baseline, this result was 
not statistically significant but may represent acute-onset ischaemia in a previously normally 
perfused limb without any peripheral arterial disease.  
 
In both the microvascular free tissue transfer flap and the transplant studies the anticipated 
peak (or continuation of a purine concentration raised above baseline) after graft reperfusion 
was not identified. In both studies venous anastomoses are completed prior to arterial there 
may be gradual “leak” of purine nucleosides into the systemic venous system prior to 
restoration of arterial inflow rather than an anticipated “surge” of accumulated purines once 
arterial inflow is restored. In addition, mechanisms to decrease metabolic rate within the 
kidney such as cooling in ice with may be effective in reducing purine production, there is 
also repetitive flushing with cold preservative solutions immediately prior to transplantation 
to prevent in-situ arterial or venous thrombosis may mean purine nucleosides was washed 
away from the graft and are lost.  
 
5.3 Non-vascular controls 
5.3.1 Demographics & surgical procedures 
This heterogeneous subgroup consisted of 80 patients undergoing a variety of surgical 
procedures with general anaesthetic this consisted of 46 males and 34 females. On validation 
of the case report form data 13 patients’ results were invalid. Purine nucleoside data was not 
sufficient for eight participants. Demographic and procedural data was missing for a further 
five participants, this was deemed sufficient to affect interpretation of any purine nucleoside 
value changes. These participants were excluded from subsequent analyses. The analysed 
cohort consisted of 38 males and 29 females. Mean age at time of surgery was 55±16 years. 
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Mean operative time was 138±81 minutes. Full cohort demographics are shown in Table J 
























































DEMOGRAPHIC N (%) 
TOTAL PARTICIPANTS 67 
SEX (M: F) 38:29 (57:44) 
AGE (mean) 55 
COMORBIDITY  
HYPERTENSON 16 (24) 
STROKE 0 (0) 
HYPERLIPIDAEMIA 9 (13) 
DIABETES 7(10) 
IHD 3 (4) 
PVD 0 (0) 
OTHER 20 (30) 
SMOKING  


























Open inguinal hernia repair 18 
Laparoscopic cholecystectomy 7 
Dental extraction 5 
Excision of skin lesion 6 
Circumcision 3 
Ocular surgery (vitrectomy/trabeculectomy) 3 
Tonsillectomy 3 
Laparoscopic gynaecological surgery 
(Salpingo-oophrectomy/cystectomy) 
3 
ENT surgery 3 
Hysterectomy 2 
Transvaginal tape 2 
Open varicose vein stripping 2 




Laparoscopic hiatus hernia repair 1 
Cerebrosinal fluid leak repair 1 
Laparoscopic inguinal hernia repair 1 
Mandibular plate removal 1 









5.3.2 Perioperative purine nucleoside changes  
Baseline purine nucleosides were 2.79±0.66µM. This was not significantly different to either 
the GA CEA or dynamic control groups. 
 
There was no statistically significant variation in purine nucleosides intraoperatively (p=0.43, 
0.72 and 0.37 at each sequential intraoperative sampling point when compared to baseline). 
Perioperative purine changes for the whole cohort are shown in Figure 12. There was also no 
significant variation by procedure or by laparoscopic/open procedure type.  
 
 
Given the heterogeneous group of surgical procedures recruited from subgroup analysis 
cannot be undertaken for many due to insufficient numbers. It was possible to perform 
subgroup analyses for those undergoing open inguinal hernia repair and laparoscopic 
cholecystectomy (n=18 and 7 respectively).  
 
Eighteen male patients underwent open inguinal hernia repair. Mean age at surgery was 
63±13 years. Mean procedure duration 116±80minutes. Seven patients underwent 
laparoscopic cholecystectomy. Mean age 60±6 years, procedure duration 130±81 minutes. 
No significant intra-group variation in purine concentration was identified in either of these 
two cohorts. Individual purine profiles are shown in Figures 13 & 14. As in the renal 
transplantation cohort the laparoscopic cholecystectomy group did exhibit a small rise in 











Figure 12 Non-vascular control whole group intra operative purine changes. Purine 
nucleosides are median values with 95%CI at time points baseline, post 
anaesthesia, mid procedure and post operatively. As each intra-operative step 
may be reached at different chronological time points (minutes) for each 
individual participant the horizontal error bars during the intra opertaive 
sampling period represent median ± 95% confidence limits of the chronological 
time point at which each operative stage was achieved. Baseline readings were 
taken prior to first case of the theatre list and therefore are not time-continuous 
with the intraoperative readings as such the post anaesthesia sample is marked 
















Figure 13 Inguinal hernia intra-operative purine changes. Purine values are median 
values with 95%CI at time points baseline, post anaesthesia, mid procedure and 
post operatively.  As each intra-operative step may be reached at different 
chronological time points (minutes) for each individual participant the 
horizontal error bars during the intra opertaive sampling period represent 
median±95% confidence limits of the chronological time point at which each 
operative stage was achieved. Baseline readings were taken prior to first case of 
the theatre list and therefore are not time-continuous with the intraoperative 














Figure 14 Laparoscopic cholecystectomy intra-operative purine changes. Purine values 
are median values with 95%CI at time points baseline, post anaesthesia, mid 
procedure and post operatively. As each intra-operative step may be reached at 
different chronological time points (minutes) for each individual participant the 
horizontal error bars during the intra opertaive sampling period represent 
median±95% confidence limits of the chronological time point at which each 
operative stage was achieved. Baseline readings were taken prior to first case of 
the theatre list and therefore are not time-continuous with the intraoperative 






Results in this cohort of patients undergoing “non-vascular, non-ischaemic” surgery with 
general anaesthetic were as anticipated; showing no significant variation from baseline 
throughout the surgical procedure in line with the hypothesis that procedures without 
ischaemia intraoperatively will not produce a rise in purine concentrations. Given the results 
obtained in the GA CEA and dynamic control cohorts the lack of a rise may be related to GA 
rather than surgical procedure and the significance of the results obtained must be questioned. 
 
It would be possible to investigate potential changes in some of these procedures performed 
under LA to exclude GA as a confounder in nucleoside production. This may be of little 
clinical significance as it would be limited to minor, superficial procedures where risk of 
significant ischaemic insult is minimal in a conscious patient. In addition to this all 
procedures in this cohort were day case or short stay procedures. Whether peripheral purine 
concentration changes would be different in surgery deemed major or major plus has not 
been identified in this cohort although given no significant rises were noted in major plus 
procedures with intra operative ischaemia (dynamic controls) it would seem unlikely that 
“non-ischaemic” procedure would cause a significantly different intraoperative purine 
profile. 
 
Following the results obtained from systemic samples in the studies above. It was 
hypothesised that obtaining samples of blood from within an ischaemic area may be able 
identify smaller rises in purine nucleoside concentrations locally prior to systemic dilution 
that are not detectable in sampling at sites distant from the ischaemic area. This limited study 
to areas of ischaemia that are readily accessible.   
 
5.4 Acute Limb Ischaemia 
5.4.1 Demographics 
Ten participants underwent lower limb orthopaedic surgery with a pneumatic tourniquet. This 
cohort included nine females and one male. Indication for surgery was exclusively 
symptomatic, radiologically proven, osteoarthritis of the knee joint. Mean age at surgery was 
58±7 years. The cohort was relatively free from major co-morbidity. Importantly, all patients 









TOTAL PARTICIPANTS 10 
SEX (M:F) 9:1 


























5.4.2 Surgical Procedures 
Five uni-compartmental (UKA) and four total knee arthroplasties (TKA) were included. In 
one patient, scheduled for a total knee arthroplasty, turbid effusion was identified on opening 
the joint capsule. The arthroplasty was abandoned and synovectomy undertaken.  
 
Mean limb ischaemic time, defined as the time between tourniquet inflation and deflation, 
was 73±18 minutes. Patients undergoing TKA had a significantly longer ischaemic time 
(94±13 minutes vs 63±10 minutes. p=0.009). Ischaemic time in the patient in whom no 
implant was used was equivalent to those who did undergo UKA. Mean time between the 
“ischaemia 40” sample and “reperfusion” sample was 28±20 minutes.  
 
5.4.3 Perioperative purine changes 
There were no significant differences in baseline purine nucleosides, these were 
2.15±1.03µM and 3.01±2.82µM in the finger prick and operated limb samples respectively 
(p=0.71). These baseline values were not significantly different to the dynamic control or 
non-vascular control study groups.  
 
After 20 minutes of tourniquet inflation operated limb purine nucleosides exhibited a 
significant increase from baseline to 15.91±6.69µM (p<0.0001). At 40 minutes of tourniquet 
inflation (ischaemia) the operated limb purines increased further to 25.57±9.98µM 
(p<0.0001). This represents a 5.2 and 8.5-fold increase respectively. On tourniquet deflation 
purine values fell to 9.82±9.57µM and within one hour of tourniquet release purine 
concentrations within the operated limb had returned to baseline values 2.26±2.25µM 
(p=0.89 vs baseline). Intraoperative comparisons between finger and limb comparisons 
cannot be made as the tourniquet prevents venous outflow from the limb. It should be noted 
there were no statistically significant changes in finger prick purine values at any sampling 
point. Finger pick values at 40 minutes of limb ischaemia were 3.59±2.22µM (p=0.55 vs 
baseline). The profile of perioperative purine nucleoside change is shown in Figure 15, Of 
note there were no significant differences in changes in purine nucleoside values between 










Figure 15 Median purine nucleosides in both the operated limb and time, matched 
systemic samples •=systemic samples, D=operated limb samples. Significant 
increases in purine nucleosides were observed in the operated limb at 20 




The results obtained in this study clearly demonstrate a significant rise in purine nucleosides 
within the ischaemic limb compared to limb baseline and time-matched systemic sampling. 
Purine nucleosides in the limb rise rapidly (in the order of minutes) and then fall to baseline 
levels on restoration of arterial inflow. These results are in line with the results of Karg et. al. 
(99) who demonstrated a purine rise during knee arthroplasty. In that study peak purine 
nucleosides were identified five minutes after tourniquet deflation, in ipsilateral femoral vein 
samples. This represents venous washout from the limb in line with restoration of arterial 
inflow. A smaller (non statistically significant) rise was identified in samples obtained from 
an antecubital vein at the same time point. This supports the hypothesis of rapid 
degradation/reuptake of nucleosides in the systemic circulation that influence determination 
of nucleosides from a sampling point distant to the site of ischaemia. The key difference 
between that study and this is the mechanism and location of sampling to observe evolution 
of changes of purines within the limb in real time.   
 
This study has demonstrated rise in purine nucleosides is rapid, a 5.2-fold increase at 20 
minutes and an 8.5-fold increase at 40 minutes of ischaemia with purine nucleosides 
returning to baseline values within one hour of restoration of normal blood flow. Indicating 
purine assessment may be sensitive to limb ischaemia in its earliest phases. Patients with ALI 
are highly likely to have an ischaemic time far in excess 40 minutes by the time they are 
assessed by a healthcare professional. Studies have reported median time from onset of 
symptoms to first contact with a healthcare professional of 24-hours (205) purine nucleosides 
at this time are likely to be grossly elevated. Purine released during prolonged acute 
ischaemia has not been studied, and at late stages of ischaemia clinical signs are likely to be 
readily apparent.  
 
Lower limb surgery with a tourniquet is a good fit initial experimental model of ALI as it 
provides a homogenous cohort of healthy patients with normal arterial supply to the lower 
limb undergoing a procedure with a consistent degree of ischaemia, where both time of onset 
and time of resolution are documented. It must be noted there are some differences between 
this experimental model and ALI occurring clinically. First, a pneumatic surgical tourniquet 
completely occludes arterial flow into the limb. In patients presenting with ALI there may 
still be inflow to the limb via collaterals from branches of the internal iliac system or via the 
profunda femoris if the level of arterial occlusion is distal to the common femoral bifurcation. 
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This remaining inflow, in a limb exhibiting signs of acute ischaemia, is by definition not 
sufficient to maintain normal oxygen delivery therefore metabolism of adenosine 
triphosphate and purine nucleoside production is likely to occur. The effect of limited 
ongoing inflow is not currently known but may have an attenuating effect on purine 
production.  
 
Second, the tourniquet restricts venous outflow for the limb meaning there is stasis of blood 
within the limb. The effect of this on the measured purine concentration is uncertain. Free 
purine nucleosides are taken up by platelets and erythrocytes to reform high energy 
phosphate compounds. There is also further metabolism downstream to urate and uric acid, 
(206) though this only occurs in the presence of xanthine oxidase and is oxygen dependent 
(14). The true total purine nucleosides released may be higher than is able to be ascertained. 
In addition, the tourniquet will obstruct venous outflow whilst it is inflated which will 
prevent purines reaching distant sampling sites meaning intraoperative comparisons between 
limb and finger samples are not applicable. No rise in finger prick purine values was 
identified on release of the tourniquet in this study, confirming purine release is related to the 
ischaemic limb.  
 
Third, Patients undergoing total knee arthroplasty for osteoarthritis are not a representative 
cohort of patients who will present with acute limb ischaemia. Whilst both conditions 
become more prevalent with age they do not have significant pre-existing PAD are less likely 
to suffer from ischaemic heart disease and diabetes than patients with PAD (207-209). In 
addition, a significant proportion of patients present with ALI on a background of peripheral 
vascular disease and chronic limb ischaemia. This is in contrast to the study population, all of 
whom do not have clinically significant peripheral vascular disease. The theoretical effect of 
ischaemic preconditioning will be discussed later, although this has not been previously 
studied. In animal models nucleoside release was sustained in chronically ischaemic tissues 
subjected to acute-on-chronic exacerbation ischaemia (59) and the observed effect on purine 
nucleoside production of acute-on chronic ischaemia in PAD patients is discussed in the next 
section.  
 
A final factor to be considered is the impact of surgery itself on purine release. Knee 
replacement requires significant soft tissue dissection, bone resection and metal prothesis 
implantation. The prosthesis is then fixed in place with polymethyl methacrylate (commonly 
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known as bone cement). This cement hardens over a period of minutes after implantation in 
an exothermic chemical reaction. The significant changes in purine nucleoside demonstrated 
have been presumed to originate primarily due to limb ischaemia created by the use of a 
tourniquet. However, as previously discussed many factors may influence purine nucleoside 
release from tissues other than ischaemia. Surgical tissue trauma and/or use bone cement may 
exert an influence on local purine nucleoside release. Strategies were employed in the study 
protocol in an attempt to mitigate theses potential confounders by seeking fresh venous 
bleeding for sampling. In addition no significant rises were noted in systemic samples in the 
dynamic control studies where potentially there was a greater degree of surgical tissue trauma 
(e.g. laparotomy). Clearly the promising results obtained here require clinical validation in 
true populations of patients with ALI to eliminate potentially confounding surgical factors as 
a source of purine nucleoside rise.   
  
5.5 Chronic Limb ischaemia  
5.5.1 Demographics 
Eight male and two female participants were recruited with a mean age of 74±9years. All 
participants recruited were scheduled to undergo lower limb bypass grafting for critical limb 
ischaemia. As anticipated cardiovascular co-morbidity was prevalent within the cohort as was 
current or previous smoking history five of ten participants were currently taking both an 
antiplatelet agent and a statin.  
 
Participants disease was again clinically graded using the Rutherford and Fontaine 
classifications. Nine participants had critical limb ischaemia with tissue loss or gangrene with 
a Fontaine score of four. Of the participants with tissue loss; five patients had a Rutherford 
score of five and four had a score of six. One participant underwent bypass for severe 
claudication (Fontaine two, Rutherford three). five participants had an SFA occlusion, three 
had popliteal occlusions and two had crural vessel disease only. Two participants had three 
vessel run off, three had two crural vessels patent and five had single vessel patent. 






5.5.2 Surgical Procedures 
All surgical procedures were performed at a single vascular hub by one of six vascular 
surgeons. Procedures were limited to infra inguinal arterial bypass grafts using autologous 
vein. Four patients underwent bypass of the femoral-popliteal segment, four patients 
underwent femoral-pedal bypass, and two patients underwent popliteal-distal bypass. Nine 
grafts used reversed vein and one bypass was left in-situ.  
 
There was a large range in duration of ischaemic time, defined as the period of time between 
application of the most cranial cross clamp and completion of the distal anastomosis, 34-136 
minutes. Mean ischaemic time was 66±40 minutes. Patients undergoing popliteal-distal 
bypasses sustained the longest period of limb ischaemia 92±19 minutes but this was not 









SEX (MALE:FEMALE) 9:1 
AGE (MEAN±SD) 74 (9) 
COMORBIDITY  
HYPERTENSION 10 
ISCHAEMIC HEART DISEASE 4 
DIABETES 3 
COPD 4 
NATURE OF VASCULAR DISEASE  
SURGICAL INDICATION  
MAJOR TISSUE LOSS 4 
MINOR TISSUE LOSS 5 
CLAUDICATION 1 
FONTAINE SCORE  
2b 1 
4 9 




















5.5.3 Perioperative purine nucleoside changes 
Baseline purine nucleoside values were 5.55±4.42 µM and 5.68±6.21 µM in the systemic and 
operated limb samples respectively. In comparison to the ALI cohort (2.15±1.03 µM and 
3.01±2.82 µM in the systemic and operated limb samples respectively) and the non-vascular 
control study group systemic sample baseline purines were significantly raised (p=0.007). 
There was marked inter-subject variation in pattern of purine nucleoside changes in both the 
systemic and operated limb samples. As such the overall changes in purine nucleoside 
concentrations were not statistically significant. Whole group purine nucleoside changes are 
shown in Figure 16. 
 
Four of the ten participants exhibited a similar purinergic response to that observed within the 
ALI cohort i.e. a rise in purine nucleoside concentrations within the operated limb on 
application of vascular clamps. These changes are shown in Figure 17. Three patients 
exhibited a late rise in purine nucleosides at the 24-hour post-operative sampling time point, 
(6.42±6.14 µM vs 2.63±0.82 µM). This trend is shown in Figure 18. The remaining three 
patients displayed no trend in perioperative nucleoside concentrations. These differing 












Figure 16 Median purine nucleosides (with 95% CI) at pre, intra and post-operative 
sampling points (baseline, vessel exposure, vascular clamp application, clamp 
release and 24 hours post operatively) given at median time at which this 
sampling point occurred (with 95%CI) sampling points. •=systemic samples, 
















Figure 17 Median purine values with 95% CI in Participants (n=7) displaying an 
intraoperative purine nucleoside concentration rise (acute-type responders).  






















Figure 18 Median purine values with 95% CI in Participants (n=3) displaying a rise at 24 
hours only (late responders). •= systemic samples, D= operated limb samples. 
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Due to technical limitations systemic and operated limb purine concentrations at first surgical 
follow up were only undertaken in one patient. Concentrations were 1.18µM and 1.5µM 
respectively.  
 
5.5.4 Clinical Outcomes 
At 30 days post operatively all bypass grafts were patent. At 90 days four grafts were 
occluded. One participant underwent further endovascular revascularisation and two 
participants underwent major amputation.  One participant was managed conservatively. 
Retrospective analysis of participants who suffered graft occlusion revealed there was no 
correlation between pre-operative purine nucleoside concentrations and early graft occlusion 
although three of the four graft occlusions occurred in participants who exhibited a “late-
type” purine response at 24-hours post operatively. In comparison, all grafts in those who 




Perioperative changes in purine nucleosides in both systemic and operated limb samples in 
this cohort of participants were clearly the most heterogeneous of all the groups of 
participants studied.   
 
In animal models it has been demonstrated chronically ischaemic tissue exhibits higher 
baseline values of purine nucleosides than normally perfused tissue (59). In humans, 
specifically in patients with PAD, baseline purine nucleosides were also raised compared to 
healthy controls (96, 98) this was identified in the local sampling CLTI study here, with both 
baseline limb and systemic samples significantly raised compared to other study populations. 
In the historical studies purine nucleosides increased above the elevated baseline on induction 
of acute-on-chronic ischaemia or increasing metabolic demand through exercise.  In the PAD 
studies this rise was achieved through exercise and was noted at lower exercise intensity than 
in healthy controls.  
 
That single model of raised baseline purines with a preserved response to exacerbation of 
ischaemia to chronic and acute-on chronic ischaemia would seem overly simplistic in the 
context of the nucleoside release demonstrated here. Some participants exhibited an intra 
operative trend towards a purine rise in the operated limb, akin to both the historic PAD 
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studies and the current local sampling ALI study, i.e. on application of arterial clamps. Other 
participants exhibited little intra operative response but appeared to show a trend of a rise in 
operated limb purine concentrations at 24-hours post operatively.  
 
It must be noted there is a difference between the baseline purine nucleosides in the CLTI 
arm of the dynamic control study and the baseline systemic samples of CLTI local sampling 
study these were 1.44±7.32 µM and 5.55±4.42 µM respectively. This variation in response to 
acute-on-chronic ischaemia between the systemic and local sampling studies as well as 
between participants within each study is likely to be multifactorial. Differences in inclusion 
criteria to each study may have resulted in differences in severity of PAD between the 
groups. Although indication for surgical intervention was most commonly “chronic limb 
ischaemia with tissue loss” this is a broad category that will encompass significant 
heterogeneity in pattern and anatomic location (single lesion vs multilevel disease), severity 
and duration of disease. The dynamic control CLTI study included a wide variety of surgical 
procedures whereas the local CLTI study recruited exclusively unilateral infra-inguinal 
bypass grafts.  
 
The dynamic control group included no patients with a Rutherford score of six and did 
include two patients with a Rutherford score of three whereas the local sampling group 
included a significant proportion of patients with a preoperative Rutherford score of six 
indicating clinical stage of PAD was more severe in patients in the local sampling study. This 
may account for the noted differences in baseline systemic purine nucleosides. Interestingly, 
in the dynamic control CLTI study one patient underwent a femoral-popliteal bypass graft for 
an SFA occlusion with a pre-operative Rutherford score of five. Baseline systemic purine 
values was 6.4µM. this patients result is consistent with both the preoperative disease pattern 
and the purine nucleoside profile of those patients recruited to the local sampling ALI study.  
 
In addition to variation in disease, the potential effects of GA that have already been 
discussed are also applicable to these studies. The increased ischaemic stress on the operated 
limb by vascular clamping may be negated by the decreased metabolic rate caused by GA. It 
is also possible chronic ischaemia secondary to PAD may offer a degree of protection against 
acute-on-chronic ischaemia via an ischaemic preconditioning phenomenon. The observed 24-
hour rise may be indicative of oxygen free radical generation and subsequent localised 
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cellular injury and hypoxia due to the inflammatory response as part of ischaemia-reperfusion 
phenomenon. It is already known that clinically significant ischaemia-reperfusion injury does 
not occur universally following infra-inguinal bypass (210). Its clinical significance is of 
uncertain importance compared to potentially life threatening reperfusion syndrome 
following revascularisation of an acutely ischaemic limb.  
 
Of further interest in this CLTI cohort was the effect of reperfusion on purine nucleoside 
concentrations in the operated limb beyond the perioperative period. Full data collection at 
first surgical follow up (approximately six weeks) was not possible due to available supply of 
SMARTchip. In the patient in which six-week purine concentration was recorded purine 
nucleosides were lower than pre-operative baseline values. Hypothetically this may be due to 
decreased ischaemic stress on the operated limb post revascularisation. Given the incomplete 
data in this part of the study this hypothesis requires significant further investigation to 
demonstrate causality related to surgical intervention. In addition, the significance of an 
apparent trend towards early graft occlusion in patients displaying a purine nucleoside rise at 
24-hours in this small sample is unknown. Whilst a predictive marker of impending graft 
failure would be extremely useful, graft failure is often multifactorial (211) and the concept a 
single biomarker may be overly simplistic. The trend observed in this small cohort requires 
significant further study to investigate purines as a predictive biomarker.  
  
5.6 Traumatic Brain Injury 
5.6.1 Demographics 
Ten participants with radiologically confirmed TBI were enrolled into the study. This group 
included five males and five females. Mean age at presentation was 68 years (range 31-96). 
Four participants were taking either antiplatelet or anticoagulant medication. Demographic 
information is displayed in Table N. 
 
5.6.2 Mechanisms of injury, types of injury, clinical measures and outcomes 
The majority of participants recruited sustained injuries as a result of falls. These varied 
significantly in mechanism from fall from standing height to fall from significant height 




In addition to analysis of purine nucleoside concentrations in the cohort as a whole, 
participant injuries were divided into two natural groups; those with “contained” intracranial 
bleeding (this group included extra and subdural haemorrhage) and “free” intracranial 
bleeding (subarachnoid haemorrhage, intraparenchymal bleeding and cerebral contusion). 
Four participants sustained contained injuries and six patients sustained free bleeding 
injuries. Four participants were identified as taking oral antiplatelet or anticoagulant 
medication; three of these four sustained free bleeding injuries whereas this only occurred in 
three of the six patients’ not taking antiplatelet or anticoagulant medication.  
 
There was significant variation in clinical signs indicating severity of injury, four patients 
showed no evidence of cognitive disturbance with a Glasgow coma scale (GCS) of 15 and a 
further four patients exhibited minor cognitive impairment (GCS 14/15). Two patients 
exhibited severe cognitive impairment (GCS 5/15 and 3/15 respectively) on admission. Three 
patients (two free and one contained) exhibited midline shift on their initial brain imaging. 












SEX (M:F) 5:5 
AGE (mean±SD) 68±23 
COMORBIDITY   
ISCHAEMIC HEART DISEASE 3 
DIABETES 1 
COPD 2 
PREVIOUS STROKE 0 
HISTORY OF BLEEDING 0 
ANTIPLATELET/ANTICOAGULANT 4 
MECHANISM OF INJURY  
FALL FROM HEIGHT 2 
FALL FROM STANDING 7 
RTC 1 


















5.6.3 Admission purine nucleosides 
Whole group admission purines were 3.07±3.13µM. Free haemorrhage injuries presented 
with higher a purine concentration than contained haemorrhage injuries (6.08±4.67 µM vs 
1.65±0.88 µM) respectively, although this difference did not meet statistical significance 
(P=0.11) (Figure 19). Patients taking antiplatelet or anticoagulant medication had an 
admission purine value of 6.05±5.70 µM whereas those not taking antiplatelet or 
anticoagulant medication median value on admission was 1.65±2.45 µM (P=0.11) (Figure 
20). Admission purine nucleosides were weakly correlated with GCS (r2=0.12) (Figure 21). 
 
5.6.4 24hr purine nucleosides 
Second readings at 24-hours were available for five of the participants recruited. Of the 
patients for which readings were not available; one patient was deceased prior to sampling, 
technical failure prevented readings in two patients and two patients were discharged prior to 
sampling. Whole group admission vs 24-hour purine nucleosides are shown in Figure 22. In 
those suffering contained bleeding injuries purine nucleosides at 24-hours was no different to 
baseline (1.72±0.99µM, p=0.66). Patients having sustained free bleeding injuries 24-hour 
purine values had fallen to 1.35±2.28µM, again this decrease was not statistically significant 



































Figure 20 Admission purine nucleosides (µM) in those taking or not taking 











































Figure 23   Comparison of admission and 24-hour purine values (µM) in the free and 





5.6.5 Clinical Outcomes 
As previously mentioned, one patient was deceased less than 24 hours after admission, one 
patient was repatriated to their native country after a prolonged hospital stay (48days). All 
other patients have made a full neurological recovery to their pre-injury neurological status. 
Mean length of hospital stay was five days.  
 
5.6.6 Analysis 
This study enrolled patients with any radiologically diagnosed traumatic intracranial injury 
and thus encompasses a wide range of injury type and severity. This included both extra and 
sub-dural haemorrhage as well as subarachnoid haemorrhage, intraparenchymal bleeding and 
cerebral contusion. Patients presented with a wide variety of clinical signs and symptoms 
from no symptoms or mild confusion (GCS of 14-15/15) through to comatose (GCS of 3/15). 
In retrospect, recruiting such a variety of intracranial injuries to a single study cohort may 
have been an overly simplistic model of TBI. This combined with a small study size has led 
to difficulty in drawing firm conclusions from the data obtained.  
 
Changes in purine nucleosides following TBI were not demonstrated to be significant, 
however the data does suggest that peripheral serum purine nucleosides may increase 
following some types of TBI. As such this pilot data may serve to pose further research 
questions rather than satisfy the hypothesis posed by this study.  
 
First, TBI that was categorised as contained bleeding (i.e. sub-dural and extra-dural 
haemorrhage) would appear not to influence nucleoside production to the same extent as 
“free” (subarachnoid and intraparenchymal) intracranial bleeding. Second, purine release 
may be related to severity of injury sustained (defined by GCS). Anatomically these findings 
are logical. Sub-dural and extra-dural venous bleeding, though intracranial, are not truly brain 
injuries. Whilst large volume dural bleeds can cause neurological symptoms or death; this is 
through volume and subsequent pressure effects in the fixed volume space of the cranial 
vault. In these injuries blood does not come into direct contact with cerebral tissue as it is 
contained by layers of dura. Increasing severity of injury can be defined as either a more 
severe injury in one area of the brain or increasing volume of brain affected as a proportion of 
the whole. Logically, both of these mechanisms may lead to an increased local inflammatory 
response, increasing cellular ischaemia and driving purine nucleoside production. Often 
minor injuries are isolated to a single category of bleeding in a discrete area of the brain 
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whereas, in contrast, major brain injuries often involve multiple categories of injury i.e. 
combined dural and parenchymal bleeding potentially involving multiple lobes of the brain.  
In the current study purine nucleosides were weakly correlated with admission GCS. Larger 
scale study is required to fully investigate this potential correlation with regard to severity 
and anatomic location of injury. 
 
Observed increases in admission purines in patients taking antiplatelet or anticoagulant 
agents are potentially a consequence of a higher proportion of “free” bleeding injuries 
sustained in this group compared to those not taking antiplatelet or anticoagulant agents. 
Anticoagulation is known to confer a risk of increased bleeding post traumatic brain injury 
but the proportion of patients suffering intracranial bleeding following head injury remains 
small (212). Rises in purine nucleosides in patients taking antiplatelet or anticoagulant 
medication may be a simple screening test to identify those patients needing brain imaging.  
 
Clearly no firm conclusions regarding the influence of anatomic location, extent of injury, 
GCS or effect of medications on purine production can be drawn from this study. Significant 
further study with greater stratification of participants by injury type and/or extent is required 
to investigate whether trends identified here are genuine.  
 
Concomitant injury is also a factor in interpretation of purine results. Although in this cohort 
mechanism of injury was predominantly fall from standing, TBI is often a high energy injury 
and therefore additional extracranial injury can occur. As purine nucleosides are not specific 
to the brain purine release can occur from concomitant extra-cranial trauma. Injuries 
sustained in the study cohort were limited to localised minor soft tissue injuries that are 
unlikely to influence systemic purine nucleoside production. In any future study the 





The results from the general anaesthetic (GA) carotid endarterectomy (CEA), dynamic 
control and non-vascular control cohorts were significantly different to the reported results 
from the previously published local anaesthetic (LA) CEA cohort (6), the results of which 
formed the theoretical basis of this work. Periods of significant intraoperative ischaemia are 
common to all these procedures. The only methodological differences between the cohorts 
were the anatomical location of ischaemia, duration of ischaemia and the choice of 
anaesthesia chosen under which to perform the procedure.  
 
6.1 Factors influencing nucleoside determination 
6.1.1 General anaesthesia 
It would appear general anaesthesia may exert an effect on purine nucleoside production and 
release confounding any interpretation of results from intra-operative purine determination. 
The lack of significant systemic (arterial) rise in purine nucleosides in any of the general 
anaesthetic subgroups (especially the GA CEA study) may indicate GA decreases cellular 
metabolic rate to a point where ischaemic purine nucleoside production does not occur, or 
their production is limited to a point where they can no longer be detected at significant 
concentrations in peripheral circulation. The influence of GA on purine production and 
systemic determination of concentrations of purine nucleosides released was unexpected 
though in retrospect, entirely predictable.  
 
The effect of GA on cerebral energy use has been extensively studied. The mechanism of 
action of many anaesthetic agents is not fully understood but it is well established that 
cerebral neuronal activity is depressed by general anaesthesia (213). It is extremely difficult 
to directly measure cerebral metabolism in vivo and a number of proxy measures are widely 
used. The vast majority cerebral metabolism is via aerobic glycolysis (214, 215) therefore 
changes in cerebral uptake of oxygen (CMRO2) and relative glucose metabolic rate (rGMR) 
are commonly used as markers for changing cerebral metabolic rate (216, 217). Multiple 
studies have used positron emission tomography techniques to study CMRO2 and rGMR in a 
variety of different anaesthetic agents. Sevoflurane was found to decrease global cerebral 
rGMR by 56% (p<0.01) (218) and propofol induced a decrease in rGMR of 54% (P<0.01) 
(217). Propofol also induced a total reduction in cerebral blood flow (CBF) of 47%. Xenon 
was shown to decrease rGMR but increase CBF (213). Volatile induction of anaesthesia has 
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also been shown to have less impact on cerebral oxygenation when compared to total 
intravenous anaesthesia (219).  
 
In addition to changes in metabolic rate, GA also affects cerebral blood flow. Under normal 
physiological conditions cerebral blood flow and cerebral glucose metabolism are tightly 
linked (220, 221). The studies above demonstrated that with many commonly used 
anaesthetic agents this coupling is lost (216). rGMR has been found to be decreased 
disproportionately (i.e. to a greater extent) when compared to CBF (217). The term luxury 
perfusion was first coined by Lassen (222, 223) in the 1960s to describe a phenomenon of 
oxygen delivery to cerebral tissue in excess of metabolic requirement. This can occur due to 
relative hyperaemia such as in response to a period of hypoxia or a profound decrease in 
cellular metabolic rate with preserved or moderately decreased CBF such as in the case of 
cellular necrosis following stroke or brain injury. Changes in metabolic rate and blood flow 
induced by GA may mimic this phenomenon by reducing cerebral metabolic rate on 
induction of anaesthesia. It can be hypothesised that the reduction in flow caused by carotid 
clamping is compensated for (in terms of ischaemic stress) by the concurrent decrease in 
cerebral metabolic rate. GA has also been shown to offer favourable neurological outcomes 
in experimental models of cerebral ischaemia and traumatic brain injury when compared to 
an remaining concious, This finding has been attributed to a lower metabolic demand on the 
brain in the short term after injury (224).  
 
There is comparatively less evidence of the effects of anaesthesia on metabolic rates of non-
cerebral tissue. Both flurane-based and high-dose fentanyl anaesthetic choices have been 
shown to decrease cardiac oxygen consumption, evidenced by increased coronary sinus 
oxygen partial pressures; 8.3±0.5 ml.dl-1 at baseline to 9.1±0.5 ml.dl-1 after induction of 
anaesthesia, and falls in myocardial oxygen volume, 9.9±4.0 ml/min-1 at baseline to 6.9±4.1 
ml/min-1 after induction of anaesthesia, in patients undergoing coronary artery bypass 
grafting (225, 226). These changes were not replicated with low-dose fentayl techniques 
(227) indicating the effect of fentanyl on metabolic rate may be dose-dependent. Glucose 
uptake and production have also been shown to fall during periods of anaesthesia (228).  
Spinal anaesthesia, whilst having no effect on cerebral metabolic rate does have a similar 
metabolic effect of peripheral tissues, has been shown to decrease resting metabolic rate of 
skeletal muscle measured via indirect calorimetry. Oxygen uptake was reduced by 25% from 
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baseline and was correlated with decreased resting-muscle activity recorded by 
mechanomyography in the anterior thigh (229).  
 
The anaesthetic agents mentioned above, or derivatives of them, are all commonly used in 
current anaesthetic practice and were used to anaesthetise participants in all of the studies 
described here. In all of the study subgroups anaesthetic choice was not standardised in the 
study protocol but was at the discretion of the anaesthetic team. As such there was variation 
within and between cohorts. The aim of the studies was not to investigate the effect of choice 
of anaesthetic agent on changes in intraoperative metabolic rate. The potential significance 
(and therefore confounding influence) of anaesthetic choice became apparent during the 
study period. In retrospect, it stands to reason that the decreases in metabolic rate induced by 
anaesthesia may be sufficient to prevent or significantly attenuate ischaemic purine 
nucleoside production as previously discussed in relation to cerebral metabolic rate. Future 
work around purine nucleosides should seek to standardise anaesthetic regimen to avoid this 
as a potential confounder.  
 
A number of factors other than anaesthetic that may influence all in vivo applications of 
purine nucleoside and SMARTchip testing have been identified. These should be considered 
during sampling and in interpretation of any results achieved.  
 
6.1.2 Mass of ischaemic tissue 
The mass of ischaemic tissue clearly has an important bearing on total adenosine triphosphate 
(ATP) metabolism and subsequent purine nucleoside release. In the experiments here; the 
procedure and the vascular inflow dictates the site of ischaemia. This in turn will result in 
varying volumes of ischaemic tissue from which purine nucleosides may be released. Studies 
performed by the united states of America military have reported the mean mass of an adult 
male leg at 10.5kg (230) an open abdominal aortic aneurysm repair would render both legs 
and the pelvis ischaemic. The total mass of ischaemic tissue is likely to be in excess of 20kg. 
Compare this to the mass of an average male human brain of 1.33kg  (231) During CEA one 
cerebral hemisphere will undergo a reduction in blood but will not be rendered completely 
ischaemic so as not to induce stroke. Continued flow is either via supply via the circle of 
Willis from the contralateral hemisphere, ipsilateral and/or contralateral vertebral arteries or 
an ipsilateral intraoperative shunt.  
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A deep inferior epigastric artery perforator (DIEP) flap has a mean mass of 644g (232). 
Therefore, at average mass, an abdominal aortic aneurysm repair may have upwards of 17.5 
times the amount of ischaemic tissue of a DIEP flap. In analysis of samples obtained from the 
systemic circulation (i.e. capillary or arterial line samples) it is possible that total purine 
release may influence determined concentrations in the samples. Whilst the aim of the 
dynamic control studies was not inter-group comparisons the differences in tissue mass, as 
well as tissue composition and metabolic rate (discussed next), serve to illustrate that a larger 
volume of ischaemic tissue may produce a greater rise in purine nucleosides than a smaller 
volume of tissue as a greater number of cells would be physiologically stressed and forced to 
metabolise ATP rather than re-phosphorylate it for reuse.  
 
6.1.3 Metabolic rate of ischaemic tissue  
In addition to mass, metabolic rate of the tissue in question must be considered. Energy 
requirements of specific tissues vary significantly throughout the body. Tissues with high 
metabolic rates are vulnerable to irreversible ischaemic damage in shorter time periods than 
tissues with lower metabolic rates; for example in the brain is most susceptible to injury 
given its high metabolic rate and limited pool of energy substrate (8, 233). Irreversible 
cerebral cellular damage is detectable in less than 20 minutes of ischaemia. Myocardium and 
kidney show irreversible damage at 20 and 30 minutes respectively (108).  
 
In vivo metabolic rate of individual organs and tissues has been estimated. First reported by 
Elia in 1992 as organ specific Ki values, in the format of resting energy expenditure (REE) in 
KcalKg-1.d-1  (Kilocalories per kilogram per day) (234). This initial estimate has been 
validated in young adults by examining oxygen consumption and carbon dioxide production 
at rest with radiological assessment of organ mass (235).  Heart, kidney, liver and brain are, 
as expected, large users of energy: 440 KcalKg-1.d-1 for heart and kidneys, 240 KcalKg-1.d-1   
for brain and 200 KcalKg-1.d-1 for liver. Skeletal muscle and adipose tissue require 
significantly less energy, 12 and 4.5 KcalKg-1.d-1 respectively. These differences in tissue 
metabolic profiles are highly likely to influence the metabolism of ATP and subsequent 
purine nucleoside release.  Tissues will comparatively lower energy expenditure may exhibit 
delayed or lower total release of purine nucleosides when compared to tissues with a higher 
metabolic demand in response to ischaemia.   
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Obesity has also been shown to influence REE. Although adipose tissue has a relatively low 
metabolic rate, its mass and distribution can vary significantly between individuals or within 
a single individual over time. The cumulative effect on energy requirement may be 
significant. Predicted REE was found to be significantly higher than measured REE in obese 
females. The hypothesis to explain this was fatty infiltration of organs and skeletal muscle 
served to decrease lean mass of the organ thus actually decreasing functional organ mass 
(236). There can also be significant differences in adipose distribution between males and 
females (237). This may exert some influence on purine production and release.  
 
6.1.4 Subject age 
Age has been shown to independently influence metabolic rate. REE in adults over 50 was 
found to decrease with increasing age by 1-2% per decade (235). This may be due to 
decreasing mass of tissue; Skeletal muscle mass has been found to decline at a rate of 3-8% 
per decade after 30 years of age (238) and cerebral tissue mass has been shown to decrease at 
5% per decade after 40 years of age (239). Though this loss of mass is multifactorial a 
reduction in absolute cell numbers has been noted. This reduction in REE may influence 
purine response to ischaemia.  
 
6.1.5 Body temperature 
Increasing temperature is known to increase metabolic rate in tissues. Each degree increase 
results in a 10-13% increase in oxygen consumption (240). Similar changes in energy use 
occur with decreasing temperature. Whilst core body temperature is tightly regulated between 
36.5 and 37.3°C peripheral and skin temperatures can be 2-4°C lower, influenced to a greater 
degree by a both physiological factors such as vasoconstriction and environmental factors 
such as ambient temperature, wind-chill and adequacy of clothing. General anaesthetic can 
influence temperature regulation via blunting autonomic physiological responses to hypo- or 
hyperthermia such as shivering or sweating, vasodilatory effects of the anaesthetic agents, 
reducing metabolic rate (and thus heat production) and skin exposure to allow adequate 
access to the surgical site (241).  External temperature control in the form of heat mats or 
blankets are commonly used to regulate intraoperative temperature but significant 
perioperative temperature variation is common (242).  
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In body extremities changes in temperature are used as a clinical signs of ischaemia with 
decreased flow leading to cooler peripheries (171). Topical cooling of limbs during ischaemia 
to minimize reperfusion injury has been described (243), although this is not a strategy 
widely employed in clinical practice. Hypothermia is intentionally used in transplantation. 
Once the organ to be transplanted has been explanted from the donor it can be stored for short 
periods in ice and cold isotonic preservation fluid (known as the cold ischaemic time). A 
reduction of tissue temperature to 15°C has been shown to reduce tissue oxygen consumption 
to 12% of normothermic tissue (244). Decreasing temperature, and therefore metabolic 
demand, of tissues has been shown to reduce ATP depletion, oxygen free radical production 
and progressive intracellular acidosis all of which are known to contribute to cellular 
apoptosis and necrosis and therefore detrimental to graft function and survival (245, 246). 
Hypothermia does not completely halt ischaemic insult to tissues and prolonged cold 
ischaemia times are still associated with ischaemia-reperfusion injury and delayed graft 
function (247).  
 
There are clear links between temperature and metabolic rate as well as metabolic rate and 
purine production. Therefore, a relationship will exist between ischaemic purine production 
and temperature that this series of studies was not designed to investigate. Decreased 
temperature in vivo during ischaemia will theoretically decrease purine production as 
metabolic demand is reduced with the reverse true for hyperthermia. Significant variation in 
temperature may require adjustment for when interpreting purine nucleoside concentrations 
clinically. If a patient has suffered prolonged exposure to temperature extremes immediately 
prior to testing this may confound any result obtained.  
 
6.1.6 Heterogeneity of tissue within the ischaemic area 
An ideal experimental model of purine release would be to study a single tissue type and its 
response to ischaemia. This is true for the carotid endarterectomy models (model of brain 
ATP metabolism) but is not for the other experiments. Ischaemia in vivo will affect an 
anatomical region, be that organ or limb, based around occlusion of the vascular supply. To 
use a lower limb as an example it is large volume and heterogeneous in its composition 
including; bone, muscle, adipose and skin. Each tissue type will contribute differently to 
purine nucleoside release with the most metabolically active tissue such as muscle 
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contributing a greater proportion of total purine nucleoside release than less metabolically 
active tissue such as adipose. 
 
Whilst an important factor to consider in a research setting the aim of SMARTchip is to be 
used as a clinical diagnostic tool, where tissue-type heterogeneity will be almost universally 
apparent and therefore is of little consequence clinically. 
 
6.1.7 Ischaemic preconditioning 
Ischaemic preconditioning (IP) is a phenomenon whereby short cycles of total, but non-
lethal, organ ischaemia followed by reperfusion offer a protective effect against cellular 
injury in subsequent prolonged ischaemia. This ischaemia can be local to the “target” organ 
or remote as periods of ischaemia of a given tissue has been demonstrated to confer 
protection against ischaemic injury in another tissue or organ (248). This phenomenon has 
been demonstrated in heart, brain, kidney (249) as well as improving muscle performance in 
trained cyclist and swimmers (250, 251). There are many hypotheses as to the mechanism by 
which IP offers protection from release of anti-inflammatory cytokines to activation of 
neuronal signalling pathways, though the exact protective mechanism remains unclear (252). 
Whilst interventional studies have focused on cycles of total ischaemia induced in either an 
upper or lower limb to offer protection against stroke or myocardial infarction the is also 
literature supporting a protective role for peripheral vascular disease against cerebral 
ischaemic damage (253). The authors hypothesised that chronic limb hypoperfusion caused 
by PAD may confer the same benefit as acute short duration ischaemia. Whilst it is known 
that PAD increases risk of myocardial infarction or stroke it would appear the extent of injury 
is decreased in patients with peripheral arterial disease compared to those without. IP has also 
been shown to extend time-to-pain in claudicants although this did not extend claudication 
distance (254, 255)  
 
In the populations studied here the ischaemic insult observed in the study may not be the first 
ischaemic event experienced. All of the CEA patients had prior neurological manifestation of 
cerebral ischaemia and the chronic limb ischaemia arm were undergoing intervention for 
clinically significant and severely symptomatic critical limb ischaemia. The potential 
influence of IP on purine release from ischaemic tissues has not been previously studied 
though prior ischaemia may confer a degree cytoprotection decreasing purine release in those 
exposed compared to “ischaemia naïve” patients.  
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6.1.8 Collateral flow 
In clinical practice, ischaemia is often not entirely absolute. Very few areas of the human 
body rely on a single arterial supply in order to reduce vulnerability to ischaemic events. 
Collateral vessels may provide ongoing inflow to an area of ischaemia. This is true within the 
brain, with potential for perfusion from the contralateral cerebral hemisphere via the circle of 
Willis or via leptomeningeal collaterals (256, 257) during periods of ischaemia. In the lower 
limb, development of collateral circulation is well documented and improvements in 
collateral circulation forms the basis of non-surgical management of patients with peripheral 
arterial disease either by enlargement of pre-existing collateral or new vessel formation (258). 
Cadaveric and radiological studies have identified collaterals in the lower limb originating 
from the profunda femoris or branches of the internal iliac system such as the superior gluteal 
or obturator arteries (259-261). It has been demonstrated peripherally that collateral supply 
will not provide full replacement of flow compared to a primary arterial supply (262) and 
development of significant collateralisation requires time. Clinically if there are signs or 
symptoms of ischaemia then the presence of collateral flow is inadequate to meet tissue 
demand for oxygen. In this circumstance ATP will be metabolised and purine nucleosides 
released.  The impact of this collateral flow on total purine production is uncertain and has 
yet to be ascertained, its relevance to future use of SMARTchip in clinical medicine may be 
negligible.   
 
6.1.9 Non-specificity of purine release.  
Purine release is universal to all cells under ischaemic stress. Whilst this offers potential for 
purine nucleoside evaluation to be applied to a wide variety of clinical conditions elevated 
serum purine concentrations will not provide a diagnosis of tissue-specific ischaemia in 
isolation. This has led to comparisons with the use of D-dimer. Whilst D-dimer has been 
shown to have a high negative predictive value for deep venous thrombosis (DVT) it has a 
low specificity, having many confounding factors that may influence results obtained. This 
non specificity has led to D-dimer being much maligned in clinical practice, especially in 
comorbid surgical populations of patients. In reality D-dimer is useful, but can only be 
treated as a screening investigation, to rule out, rather than diagnose DVT (263, 264). It may 
be necessary to apply a similar logic to purine nucleoside use as a biomarker; its use and 
interpretation should be judicious and in line with strong clinical suspicion of a specific 
“ischaemic diagnosis”.  
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6.1.10 Surgical stress response 
The initiation of a catabolic endocrine state as part of the metabolic stress response to tissue 
trauma and surgery (265) could also influence increased purine nucleoside release.  No 
significant rise was identified in the non-ischaemic surgery control cohort possibly meaning 
significant purine response to surgical trauma may not occur. Anaesthesia (both general, local 
and regional blockade) attenuate this stress response (265) and therefore may also exert an 
effect on purine nucleoside production. 
 
6.2 Procedural and technical factors 
In addition to in vivo patient and tissue factors influencing purine nucleoside determination 
there are a number of experimental procedural factors that may influence sampling and result 
interpretation in these studies.  
 
6.2.1 Site of sampling 
A factor that has become apparent in the experiments detailed here is the potential effect of 
sampling site in relation to the area of ischaemia. This is notable in the differences in results 
between the systemic and local sampling study designs whereby significant increases were 
only able to be identified from samples within ischaemic tissue. As previously documented 
purine nucleosides are inherently unstable within the circulation, half-lives of adenosine, 
inosine and hypoxanthine have been shown to be very short. Enzymatically driven 
metabolism to uric acid and as well as re-uptake and re-synthesis of ATP occurs rapidly 
(266). Whilst SMARTchip allows ease of sampling from capillary blood, most commonly 
obtained via finger prick sampling, results of the experiments detailed have raised the 
possibility that sampling from a site that is distant to the site of ischaemia may not produce a 
detectable rise in purine nucleosides.  
 
Time taken for blood to circulate will influence the degree of metabolism and uptake. Under 
normal conditions circulation time would be in the order of seconds though there are multiple 
factors that can influence circulation time including cardiac output, peripheral vascular 
resistance, temperature and position of the sampling site relative to the heart (267, 268) all of 
which are influenced by a general anaesthetic. It may be that the extra time in circulation (i.e. 
time taken for circulation between jugular bulb and radial artery in the CEA study) is 
sufficiently long to enable significant metabolism/re-uptake to occur in a similar fashion to 
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the technical issues experienced in early experiments of purine concentration determination 
from serum prior to the development of “stopper” solutions to yielding negative results.  
 
Given this, attempting to sample from (or as near as possible to) the ischaemic tissue would 
negate this time delay and thus minimise opportunity for purine metabolism between release 
from ischaemic cells and sampling. This is very dependent on site of ischaemia. The 
experiments here have examined ischaemia across a wide variety of tissue types. Whist it is 
not feasible to sample directly from vital organs, limb ischaemia does lend itself to this local 
sampling strategy. 
 
6.2.2 Sample timing 
Using SMARTchip, each sample analysis cycle takes a total of 345 seconds (5.75 minutes) to 
complete. This comprises of 165 seconds calibrating the SMARTchip and 180 seconds 
analysing. When comparing time matched samples, the minimum interval between sample 
timings that can be achieved is 510 seconds (8.5 minutes) comprising of one full analysis 
cycle and an additional calibrating cycle before the next analysis can begin. A further 
potentiostat, in order to run samples truly in parallel, was not available. The second time 
matched sample was not obtained until the analysis equipment had undergone calibration and 
was ready to analyse to prevent metabolism/re-uptake after sampling.  In clinical practice as a 
diagnostic aid where a single sample is required at a given time this sample timing is not an 
issue. In the studies here, it must be noted that the paired samples are offset by approximately 
eight minutes. To standardise this difference paired samples were always obtained in a set 
order within each experiment.  
 
6.2.3 Local tissue trauma 
Purine release has been identified from traumatically injured tissues. Inflammatory response 
in reaction to tissue trauma results in local cellular ischaemia and subsequent purine release. 
This is a potential confounder within the local sampling studies. Initially sampling was 
attempted from within the sterile surgical field but distant to the operative site via small stab 
incisions or attempted direct puncture of visible skin veins. This was unsuccessful as 
bleeding from the skin was not sufficient to obtain samples. Where samples were obtained 
from within surgical incisions fresh venous bleeding from deep tissues was sought. Any 
pooled blood was not used for analysis in order to minimise the effect of tissue trauma on 
sample analysis.   
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Anecdotal evidence obtained during these studies would suggest where an initial finger prick 
does not yield sufficient blood for analysis excessive “milking” of blood from a sampling site 
may also produce a degree of tissue trauma to affect purine nucleoside concentrations and as 
such should be avoided. 
 
Total purine production as a consequence of ischaemia is ultimately dependant on all of the 
factors discussed above. Each of this will influence nucleosides to different extents. Tissue 
volume and metabolic rate would seem to be the most important as they offer the greatest 
degree of differences between tissues investigated. Tissues with a higher metabolic rate will 
exhibit a rise in purines earlier in ischaemia than those with a lower metabolic rate, this is of 
clinical significance as a high metabolic rate is a feature of organs than fulfil essential 
functions for homeostasis. For example brain, heart, kidney and liver have the highest 
identified metabolic rates and all carry out functions essential to life (235). A diagnostic aid 
for the early detection of ischaemia is valuable in “high energy” organs in order to identify, 
investigate and intervene to relieve ischaemia (if clinically necessary) early as ischaemia of 
these organs will result in damage leading to loss of function at shorter durations of 
ischaemia than tissues with a lower metabolic rate. 
 
6.3 Sensor development 
6.3.1 SMARTchip development 
Despite technological advances to enable SMARTchip development its production and use 
has remained challenging. Currently the sensor requires refrigerated storage at 4oC. Ensuring 
safe, temperature controlled and monitored storage for a product that may be infrequently 
used may be challenging. An ideal sensor would need to retain functionality over a pronged 
period of time at ambient temperature.   
 
The current biosensor is designed so that the biological sample is applied directly to the 
uncovered sensor, this mean the electrode ends are exposed and unprotected. Care must be 
taken during production, storage, handling prior to sampling, application of calibration 
solutions and application of the sample to be analysed. Any contact with the sensor prior to 
adding sample my cause damage to the electrode or polymer coating, leading to inaccurate or 
unreliable results. Use of SMARTchip clinical practice would require a more robust sensor 
and/or protective covering. An ideal protective cap is robust to direct contact, does not 
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contact the sensor and does not obstruct application of biological samples for analysis. 
Various iterations of sliding mechanisms and fixed covers that rely on hydrophilic coatings 
and capillary hydrostatic forces to transport sample from application site to sensor have been 
trialled, their refinement is an ongoing process. It has been noted that constituent of fluid is 
an important factor in how the cap behaves. Blood samples are more viscous than the buffer 
solutions and are more challenging to cover the whole sensing area than the buffer solutions. 
Further development is required prior to larger scale testing to ensure the biosensor is robust 
and reliable for results to be interpreted with the degree of confidence needed in clinical 
practice.  
 
Relay of current along the chip body from sensor head to the potentiostat requires complete 
electrical isolation, this is achieved by a printed layer of an electrically inert polymer. 
Microscopic breaches in the covering leading to exposed electrode surface have been an 
ongoing issue during SMARTchip development. These breaches, leading to contact between 
electrodes and sample away from the correct position on the sensor lead to invalid results. As 
with sensor contact, in a research setting this can be adjusted for as results can be validated 
from the raw data and repeated if necessary though this is unlikely to occur in clinical 
practice especially in emergency situations. Work is ongoing to refine biosensor production 
and quality control will need to be validated prior to larger scale validation of SMARTchip. 
 
Currently the biosensor equipment consists of a potentiostat connected to a laptop PC with 
the appropriate analysis software. Next generation biosensor development is already nearing 
completion. This improvement condenses the bulky, multi-piece equipment into a single 
battery powered, hand-held unit.  
 
This progression and miniaturization of the technology is highly significant and represents a 
further step-change to open the door to potential of a validated biomarker that can be 
ascertained from capillary blood in a relatively short time frame on a portable device in a 
primary care, pre-hospital or outpatient setting Where its use (and results) may be of greater 
importance to aid diagnosis and triage patients appropriately to specialist services than within 





6.3.2 Development of purines as a biomarker 
As discussed previously purine nucleoside release occurs from a wide variety of cells and 
tissue types when physiologically stressed. This, whilst offering the advantage of applying 
the principle of purine nucleoside assessment to a wide variety of clinical scenarios, may 
present challenges in differentiating purine release by ischaemic tissues from potential purine 
release from concurrent physiological processes i.e. concurrent non ischaemic tissue injury or 
surgical stress response. Whether this potential for interference is a confounding factor in the 
presence of significant ischaemia is unknown and not conclusively demonstrated in this body 
of work. Quantification of and correction for any non-ischaemic or otherwise confounding 
purine release would necessary to validate purine nucleoside use as a biomarker.  
 
This series of studies has grouped adenosine, inosine and hypoxanthine together as collective 
“purine nucleosides”. SMARTchip currently does not differentiate between these nucleosides 
but gives an overall combined purine nucleoside result. This differentiation may offer an 
avenue of refinement in purine assessment in vivo. Some historical studies (23,77,88,97) have 
noted differences in changes between the different purine nucleosides during the same 
ischaemic stress event. Future development in purines as a biomarker may involve 
investigation into quantification of individual nucleosides rather than purine nucleosides as a 
group. If there is a differential increase in one nucleoside from a specific tissue it may be 
possible to negate (in part or whole) any confounding purine release, increasing test 
specificity thus making purine nucleoside determination more reliable as a biomarker of 
ischaemia in clinical practice.  
 
As with interpretation of the result of any clinical investigation, the need for correlation of 
purine nucleoside assessment with a patients’ physical symptoms and clinical signs will be 
required. 
 
6.4 Potential clinical applications 
All of the experiments detailed here are small scale studies providing proof-of-concept pilot 
data only. Results in acute limb ischaemia (ALI), chronic limb threatening ischaemia (CLTI) 
and traumatic brain injury (TBI) are encouraging. Further work is required in each case to 
validate the results obtained here in clinical populations of patients. Given the confounding 
effect of GA the use of SMARTchip as an intra operative biomarker of evolving ischaemia 
may be limited, however, its use in populations of patients with significant ischaemia away 
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from an intra-operative setting may still be of clinical value. The new sensing technology also 
may re-open avenues of research previously discontinued due to technical challenges. 
 
6.4.1 Carotid Endarterectomy 
Whist it appears GA confounded appreciable purine rise in this experiment; no neurological 
events were noted within the study cohort. Further work is needed specifically focusing on 
those patients in whom significant cerebral ischaemia is detected. It may be that in our 
relatively small cohort collateral cerebral blood supply was adequate or the practice of 
prophylactic shunt insertion prevented significant ischaemia from occurring. The concept of a 
study only investigating patients with significant intraoperative cerebral ischaemia has a 
significant problem as there is no validated gold standard comparator test and it would be 
unethical to impose a never shunt policy on a study population. In theory, as there is no 
demonstrated superiority of routine vs selective vs never shunting (125) a study with a 
routine shunt policy and intraoperative purine sampling, comparing patients with and without 
post-operative evidence of neurological insult would be possible. However, given the low 
incidence of perioperative stroke, numbers of patients required to reach statistical 
significance is likely to be prohibitively large.  
 
6.4.2 Acute limb ischaemia 
The use of a tourniquet has allowed investigation of ALI in this experimental model. It offers 
reproducible acute, absolute interruption of blood inflow to a limb that is appropriate for this 
proof-of-concept study. The differences in this form of ALI and ALI presenting clinically 
have already been discussed.  
 
The next step towards the use of purine nucleosides as a biomarker of acute limb ischaemia is 
to validate the results obtained here in patients presenting to medical practitioners with acute 
limb ischaemia. A larger scale follow on study recruiting patients presenting to secondary 
care with suspicion of acute limb ischaemia is needed. This study may also be able to identify 
if purine nucleoside determination can differentiate ALI from other causes of acute onset 
limb pain including progression of chronic ischaemia, spinal cord or nerve root compression, 
neuropathy and deep vein thrombosis (140, 269). Purine release in these ALI mimics has not 
previously been studied. It must be demonstrated that purine nucleoside determination results 
in improved patient outcomes, in terms of limb salvage, following ALI above current 
diagnostic methods used.  
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Ultimately SMARTchip may be most useful in clinical practice outside of a hospital setting, 
in primary care or during pre-hospital emergency care in order to appropriately triage patients 
towards hospitals that are able to offer vascular surgical services.  Use of purines may also be 
applied in an emergency department setting where there is diagnostic uncertainty; though this 
is less important given there is likely to be timely access to appropriate imaging modalities 
and vascular specialist clinical assessment.  
 
In addition, further investigation is required into purine rises in systemic samples in patients 
with limb ischaemia. Without a tourniquet restricting venous outflow it may be possible to 
obtain significantly raised and reliable results from finger prick samples in the absence of 
GA. 
 
6.4.3 Chronic ischaemia  
Nucleoside determination intra operatively in patients undergoing revascularisation may be 
of little clinical value. The differences demonstrated between baseline purine values in 
patients with Peripheral arterial disease (PAD) and patients without PAD are of clinical 
interest. As discussed with reference to the ALI study raised purine nucleosides in finger (or 
toe) capillary blood samples in patients with suspected PAD/CLTI could be a useful 
screening tool for non-vascular specialists to initiate referral to specialist services. In 
addition, change in nucleoside concentrations over time may be of interest to vascular 
specialists as hypothetically nucleosides would increase as PAD progresses and ischaemic 
stress on the limb increases. Purine nucleosides potentially could aid identification of patients 
who may need surgical or endovascular revascularisation prior to significant tissue loss 
developing. Purine nucleosides as a marker of PAD progression has not been investigated in 
this series of studies or any historic work.  
 
Future work into purine nucleosides in CLTI/PAD could focus on patients in primary care or 
those referred to vascular services with symptoms consistent with PAD and correlate purine 
nucleosides with clinical and radiological findings in order guide appropriate referral to 
vascular services. Serial purine determination over time may define pattern of purine 
nucleoside change over time in the presence of PAD to determine usefulness as a marker of 
disease progression and potentially effect of medical management strategies of ischaemic 
stress within the limb. Comparisons of pre and post-operative nucleoside concentrations may 
also be useful to gauge success of intervention although ultimately clinical assessment in 
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terms of symptom resolution and wound healing is most likely of greater importance to both 
patient and clinician.  
 
6.4.4 Traumatic brain injury 
The small study presented here has identified purine nucleoside release may occur following 
TBI and can be detected in the peripheral blood circulation, although results were not 
conclusive. For SMARTchip to be clinically useful continued recruitment of patients with 
TBI is required to validate the preliminary findings of this small study.  
 
Patients with an altered GCS, significant cognitive impairment or focal neurological deficit 
suggestive of TBI will need radiological imaging to assess type, extent and location of TBI in 
order to adequately assess need and to plan for surgical or radiological intervention. In these 
cases, assessment of purine nucleosides may be superfluous. Purine assessment may be of 
greater value where there are no clinical signs of TBI or baseline cognitive state of the patient 
is unclear but there is clinical suspicion of TBI based on individual patient risk factors or 
mechanism of injury. For example, purine nucleoside concentrations may be of use in a 
patient, at increased risk of bleeding due to taking either an antiplatelet or anticoagulant 
medication, who has sustained a fall and potential brain injury but has a normal or mildly 
reduced GCS (i.e. 14) to guide the need for detailed radiological imaging and/or admission 
for observation. 
 
If findings of this study are validated SMARTchip may have potential to be used pre-hospital 
to guide first responders as to whether attendance at hospital is necessary, if so, it may also 
influence choice of hospital towards one with appropriate neurological or neurosurgical 
facilities.  
 
Correlation is needed between peripheral nucleoside concentration (on admission and during 
recovery) and radiological appearances, GCS, other biomarkers currently under investigation 
in the assessment of TBI such as S100 calcium binding protein b and glial fibrillary acidic 
protein as well as both short term and long term outcomes both neurophysical and 
neuropsychiatric in order to validate its use. Clearly a great deal of further work is required 




Extrapolation of results into other clinical scenarios  
6.4.5 Intestinal ischaemia 
Intestinal ischaemia both vascular and non-vascular in origin remains a diagnostic challenge 
for clinicians. It may affect 1 in 1000 hospital attendances (270) with significant mortality 
rates of up to 80%. Early clinical features can be non-specific which introduces potential for 
diagnostic delay, compromising patient outcomes (271). Both traditional and novel 
biochemical markers such as lactate, c-reactive protein, intestinal fatty acid binding protein 
and a-glutathione S-transferase have been extensively investigated as a potential biomarker 
but all have ultimately shown poor performance in aiding a diagnosis of bowel ischaemia in 
clinical practice (270, 272). CT imaging is also useful in aiding diagnosis but may be 
contraindicated in renal failure or contrast allergy. Laparotomy remains the gold standard in 
obtaining a diagnosis but carries significant morbidity in itself. The need for a simple marker 
of early ischaemia remains.  
 
Whist no significant change in peritoneal purine nucleosides during intestinal ischaemia has 
been noted (107) changes in serum purine nucleosides have not been investigated. Purines 
may offer potential as an early diagnostic aid in patients with a suggestive history and/or 
other supportive investigations. A potential confounder to this is in cases of ischaemia that is 
non-vascular in origin e.g. bowel strangulation. This obstruction prevents venous outflow as 
well as arterial inflow therefore a rise in capillary or venous blood samples may not be 
appreciated due to restriction in venous outflow. Venous outflow is not restricted in cases of 
arterial embolism, in situ thrombosis or ischaemia due to hypoperfusion. These aetiologies 
are less common (273) but it may be possible to detect a rise in purine nucleosides more 
readily than non-vascular causes. 
 
6.4.6 Acute compartment syndrome 
Acute compartment syndrome following surgery, ischaemia or trauma is rare (274). Its 
diagnosis can be further complicated by non-specific symptoms, concomitant analgesia or 
patient sedation. Consequences of a missed or delayed diagnosis can be catastrophic for the 
patient with potential for permanent neurological dysfunction, limb loss or death (275). 
Diagnosis in clinical practice relies on clinical examination (tense compartment to palpation, 
pain on passive stretch) or compartment pressure monitoring, which is invasive and often not 
routinely available. Given the pathophysiology of acute compartment syndrome is vascular 
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compromise secondary to increased compartmental pressure (276), logically purine 
nucleoside concentrations would be increased in its early phases. As with many other 
potential applications discussed here the role of purine nucleosides in compartment syndrome 
has not been studied. The noted rise in purine nucleoside concentrations at 24-hours in the 
CLTI cohort, attributed to reperfusion combined with the acute rise during ischaemia in the 
ALI cohort would support purine nucleosides as potential marker of acute compartment 
syndrome. Restriction of outflow may confound systemic sampling though sampling directly 
from the limb in question may be possible. Any potential study to investigate this, may be 
hampered by the rarity of the condition and the judicious use of fasciotomies prophylactically 
to prevent the development of compartment syndrome in “at risk” patients.  
 
6.4.7 Myocardial infarction 
Purine nucleoside release as an early biomarker in response to myocardial ischaemia or 
infarction (MI) has been previously studied with encouraging results in clinical settings 
sampling peripheral venous blood (5, 13, 38). Effectiveness of SMARTchip has yet to be 
studied in the context of chest pain or myocardial ischaemia.  
 
Early intervention in patients with ST-elevation myocardial infarction (MI) in the form of 
percutaneous coronary intervention (PCI) within 120 minutes of first contact with a health 
professional is essential to effectively treating myocardial infarction (277). Delays between 
symptom onset and/or first medical contact and percutaneous coronary intervention (PCI) 
have been shown to increase all-cause mortality and risk of heart failure (278). Whilst in 
patients with non ST elevation MI current guidelines advocate a medical rather than 
interventional approach to initial management timely assessment, via catheter angiography, 
of future risk and management planning is essential (279). 
 
Theoretically, the potential advantage of SMARTchip over other commonly used biomarkers 
such as troponin assay or other purine detection mechanisms as reported by Farthing et. al. 
(5) is the use of battery powered analysis units and capillary blood sampling to provide rapid 
results in a community or pre-hospital setting. In conjunction with clinical assessment and 
existing out of hospital diagnostic aids such as electrocardiogram may allow healthcare 
professionals to expedite triage and appropriate transfer to secondary care cardiology services 
with PCI capabilities.  
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A study to obtain pilot data (purine nucleoside concentrations from finger prick samples) in 
patients presenting to cardiology services with confirmed myocardial infarction is needed to 
validate SMARTchip in this setting which can then be expanded to include patients 
presenting with chest pain to determine sensitivity and specificities against chest pain of non-
cardiac origin.  
 
6.4.8 Stroke 
Building on the results of SMARTchip in cerebral ischaemia (6, 81) the purines for rapid 
identification of stroke mimics (PRISM) study (280) is currently investigating the potential of 
SMARTchip in a pre-hospital setting. Patients with suspected stroke will be recruited, with 
finger prick testing undertaken by paramedics in the community with the aim of identifying 






The purinergic role in vivo is complicated. Despite a metabolic pathway universal to all cells 
during ischaemia multiple factors influence purine nucleoside formation, release, metabolism 
and reuptake. Obtaining results that are accurate, reproducible and reliable in both research 
and clinical settings has been exceptionally challenging. As such, their use as a biomarker, 
whilst recognised for over 50 years has not been realised. Advances in understanding of 
purine metabolism combined with technological advancement would appear to have offered 
potential for purine nucleosides to now be a useful biomarker in clinical practice. Challenges 
remain in sampling analysis and result interpretation in the context of varying duration, 
degree and anatomic location of ischaemia.  
 
This body of work initially focused on purine nucleosides as an intraoperative biomarker of 
ischaemia from systemic arterial samples. Significant rises in nucleoside concentrations were 
not demonstrated. It would appear that a combination general anaesthetic agents and site of 
sampling prevent useful measurement of in changes nucleoside concentrations from 
peripheral sites intra-operatively. Local capillary sampling from within an area of ischaemia 
intraoperatively may avoid these confounding influences encountered in sampling from sites 
distant to ischaemia.  
 
Whilst use of purine nucleosides as an intra-operative (with general anaesthetic) biomarker 
would appear to be limited to peripheral sites, ultimately meaning they may actually be of 
little value clinically, potential for their use in surgical populations away from the operating 
theatre as well as in non-surgical populations remains. A model of acute limb ischaemia has 
been shown to cause a significant rise in purine nucleosides. There is also evidence of purine 
release from chronically ischaemic limbs and in some types of brain injury although the 
nature of this release would appear to be complex and has not been fully explained in this 
work. Significant further work is required to fully understand the profile of purine nucleoside 
release in these contexts as well as to validate purine nucleosides as a biomarker of ischaemia 
in clinical practice and true patient populations. 
 
As the pathways of purine metabolism in ischaemia are universal to all cells and cells have to 
be metabolically active (and therefore still viable) in order for purine nucleosides to be 
produced it would appear future potential of nucleosides as an early (and therefore clinically 
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useful) biomarker of ischaemia is widespread across a range of ischaemic scenarios in both 
pre-hospital and secondary care settings. Expansion of this initial proof-of-concept work is 
required to both validate the results obtained here and investigate further area of clinical 
utility before the use of purine nucleosides as a biomarker of ischaemia in clinical practice 
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